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Abstract
Angiotensin-Converting Enzyme (ACE) plays an essential role in blood pressure regulation 
and ACE inhibitors are widely used to treat cardiovascular disease.  Two isoforms exist, 
somatic ACE (sACE) consisting of two homologous domains, N- and C-domain, and testis 
ACE (tACE), corresponding to the C-domain of sACE.  Despite a high degree of sequence 
identity, these two domains display marked differences in substrate and inhibitor specificity. 
Furthermore, the C-domain of ACE has been implicated to play  a dominant role in blood 
pressure control.  It has therefore been suggested that development of ACE inhibitor 
treatments that selectively  block the C-domain will result in decreased side-effects compared 
to current therapies.  Analysis of three-dimensional structures of tACE in complex with 
domain-specific inhibitors has enabled the identification of key active-site residues potentially 
playing a role in domain selectivity.  To investigate the contribution of such residues, a series 
of C-domain mutants was generated containing single and multiple N-domain active-site 
substitutions.  These constructs were used to characterise specific interactions using domain-
selective inhibitors and fluorogenic peptides.  Mutants tested with the fluorogenic peptides 
displayed minimal, if any, acquisition of N-domain-like catalytic properties.  Of the single 
mutations, S2 (F391Y, tACE numbering) and S1 (V518T) pocket  substitutions caused the 
largest decreases in affinity for the C-selective phosphinic inhibitor RXPA380 (34-fold) and 
keto-ACE derivatives (14-26 fold), respectively.  The V379S mutation caused an unexpected 
increase in affinity (2-10 fold) for C-selective inhibitors containing a P2’ Trp  that could be 
explained by the formation of a water-mediated hydrogen bond interaction resulting from 
rearrangement of inhibitor and protein side-chains within the S2’ pocket.  Multiple mutants 
containing an N-domain-like S2’ pocket combined with the S2 F391Y substitution (S2’F) 
caused the most notable shift  in Ki from that of tACE for the highly selective phosphinic 
inhibitors, RXPA380 (Ki’s tACE = 69 nM; S2’F = 5300 nM) and N-specific RXP407 (Ki’s 
tACE = 2800 nM; S2’F Ki = 16.1 nM).  This work identifies key residues contributing to the 
domain selectivity of ACE, and highlights the complex combination of effects involved in this 
phenomenon.  Furthermore, it  provides useful insight for the further design of domain-
selective inhibitors.
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Z-FHL  Z-Phe-His-Leu
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1.1 The renin-angiotensin and kallikrein-kinin systems
The renin-angiotensin system (RAS) (figure 1.1) plays a critical role in the regulation of 
blood pressure, as well as fluid and electrolyte homeostasis (reviewed in Inagami, 1994; 
Fyhrquist and Saijonmaa, 2008).  Hypotension, defined as low blood pressure, is a result of 
decreased sodium levels or effective plasma volumes, which stimulates renal release of renin 
(Goldblatt et al., 1934; Houssay. and Fasciolo, 1937; Page and Helmer, 1940).  Renin releases 
the N-terminal peptide angiotensin I (Ang I) from the glycoprotein angiotensinogen, a 
prohormone secreted by the liver (figure 1.1) (Inagami, 1994).  Ang I is in turn converted to 
the potent vasopressor angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) 
(Skeggs et al., 1954; Skeggs et al., 1956).  Ang II mediates a variety of functions through two 
receptors, angiotensin II type I (AT1) and type II (AT2) receptors (de Gasparo et  al., 1995). 
AT1 is responsible for actions such as vasoconstriction, aldosterone release, salt and water 
reabsorption, sympathetic activation and cell growth proliferation (Timmermans et al., 1992; 
Timmermans et al., 1993).  The AT2 receptor effects however, seem to offset those mediated 
by AT1 and include vasodilation, inhibition of growth and proliferation, differentiation and 
apoptosis (Horiuchi, 1996; Csikós et al., 1998).  This receptor is highly abundant in the 
developing foetus, however levels lessen rapidly after birth (Lazard et al., 1994; Shanmugam 
and Sandberg, 1996).  
The complexity  of the RAS is further demonstrated by several other biologically  active 
angiotensin peptides (figure 1.1).  Aminopeptidase A produces the metabolite angiotensin III 
(Ang III) from Ang II, which mediates similar functions to its precursor via the same 
receptors, discussed above (Wright and Harding, 1997; Ardaillou and Chansel, 1997).  The 
angiotensin type IV (AT4) receptor specifically binds the angiotensin III cleavage product, 
angiotensin IV (Swanson et  al., 1992; Albiston et al., 2001), and has been associated with a 
number of actions such as neuronal development, renal and cerebral blood flow and memory 
gain and retention (Wright and Harding, 1997).  Angiotensin(1-7), produced mainly  by the 
action of the ACE homologue ACE2 on Ang II (Donoghue et al., 2000; Turner et  al., 2002), 
displays interesting vasodilatory effects, particularly within an activated RAS (Nakamoto et 
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al., 1995; Iyer et al., 2000; Nakamura et al., 2003), and has been shown to mediate these 
through the G-protein-coupled receptor Mas (Santos et al., 2003).
Figure 1.1.  The renin-angiotensin and kallikrein-kinin systems (adapted from Acharya et 
al., 2003; Fyhrquist and Saijonmaa, 2008).  Neutral endopeptidase (NEP); aminopeptidase A 
(AMPA); aminopeptidase M  (AMPM); BK receptor (B2).  Solid lines indicate conversion of a 
peptide to a product, while broken arrows indicate action of a hormone on a receptor.
The kallikrein-kinin system (KKS) (figure 1.1) is chiefly a tissue-based system, which in 
some animals has been shown to play a role in a variety of functions including blood pressure 
regulation, sodium balance and inflammatory processes (Katori and Majima, 1996; Damas, 
1996; Yang et al., 1997).  In humans, plasma kallikrein produces the vasodilator bradykinin 
(BK) from the glycoprotein precursor, high molecular weight kininogen  (reviewed in Bhoola 
et al., 1992).  Tissue kallikrein is able to cleave this kininogen, as well as a second low 
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molecular weight kininogen, to form the product kallidin.  These kinins mediate their actions 
mainly through the more dominant kinin type II (B2) receptor, while products of kinin-
carboxypeptidase activity (des-Arg9-bradykinin and des-Arg10-kallidin) have more potent 
effects on a second kinin type I (B1) receptor induced during tissue damage (Regoli et al., 
1989).
There is a unique interplay between these two systems, in which actions of the plasma KKS 
offset effects of the RAS (figure 1.1) (Schmaier, 2002).  For example, plasma kallikreins have 
been shown to activate pro-renin (Sealey et al., 1979), and are able to produce Ang II directly 
from the angiotensinogen prohormone (Yamaguchi et al., 1991; Sasaguri et al., 1995). 
Furthermore, in addition to its role in Ang II production in the RAS as discussed above, ACE 
is responsible for the sequential degradation of the vasodilator BK at the Pro7-Phe8 and Phe5-
Ser6 scissile bonds (Baudin, 2002), into inactive products (Erdos and Yang, 1967; Yang et al., 
1970; Yang et al., 1971).  Moreover, besides the effects of increasing and decreasing BK and 
Ang II levels, respectively, ACE inhibitors are also able to re-sensitise desensitised B2 
receptors to BK, via initiation of a process involving interaction between ACE and the 
receptor (Marcic and Erdös, 2000).
The critical role of the RAS has been clearly  demonstrated by a variety of transgenic mouse 
models.  Angiotensinogen (Kim et al., 1995), renin (Yanai et al., 2000), ACE (Krege et al., 
1995; Esther et al., 1996) and AT1 receptor (Ito et al., 1995; Chen et al., 1997; Tsuchida et al., 
1998; Oliverio et al., 1998) knock-out mice all present with a significantly  lowered blood 
pressure compared to wild-type animals.  This blood pressure abnormality has been attributed 
to the absence of Ang II and not to BK accumulation, as evidenced by another mouse model 
lacking both the ACE and B2 receptor genes, and displaying a similar hypotensive phenotype 
to that observed in the ACE knock-out model (Xiao et al., 2003).  These studies clearly 
indicate that no other biological system is able to compensate for this Ang II deficiency, and 
highlights the fact that the RAS, particularly ACE, AT1 receptors and renin, is an ideal target 
for the treatment of hypertension.
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1.2 ACE - a zinc metallopeptidase
ACE (EC 3.4.15.1) is a dipeptidyl carboxypeptidase and a member of the gluzincin family 
(MA clan) of metalloproteases (Corvol and Williams, 1998).  It is expressed as two isoforms, 
namely somatic ACE (sACE) and germinal or testis ACE (tACE) (Ehlers et al., 1989; 
Soubrier et al., 1988).  Both are transcribed from a unique 21 kilobase ACE gene situated on 
chromosome 17q23, made up of 26 exons and under the control of two separate promoters 
(figure 1.2) (Howard et al., 1990; Hubert et al., 1991).  The sACE promoter is 5’ to the first 
exon, and the mRNA contains 25 of the exons, with the thirteenth exon spliced out.  The 
germinal promoter is contained within intron 12, upstream to exon 13, and the tACE 
transcript contains exons 13 through to 26.
ACE is attached to the cell membrane via a transmembrane region, and contains both a small, 
C-terminal intracellular region, and a large N-terminal highly glycosylated extracellular 
region (figure 1.2) (Soubrier et al., 1988).  The ectodomain of the 1277-residue sACE 
comprises two homologous domains, called the N- and C-domains.  These two domains are 
believed to be a result of a gene duplication event, displaying an overall sequence identity  of 
approximately 60 % (figure 1.3).  
Each of these domains contains an active-site with the zinc binding motif HEMGH, and 
sequence identity increases to 89 % within this region.  The somatic form is widely  expressed 
in a variety of tissues including vascular endothelium, renal proximal tubule epithelium, 
intestinal epithelium and macrophages (Takada et al., 1984; Chai et al., 1987; Sibony et al., 
1993).  The testis ACE isoform plays a role in fertility (Hagaman et al., 1998), is expressed 
exclusively  in male germinal cells (Langford et al., 1993) and consists of only one 
extracellular domain, which except for the unique 36-residue N-terminal region, is identical to 
that of the C-domain of sACE (figure 1.2).  A soluble form of the sACE enzyme is present in 
plasma, and is a result of cleavage of the protein from the cell membrane, by an as yet 
unknown secretase (Ehlers et al., 1996; Woodman et al., 2000).
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Figure 1.2.  Diagrammatic representation of the ACE gene and gene products.  The ACE 
gene, situated on chromosome 17q23, contains two separate promoters (somatic and 
germinal) giving rise to two different isoforms, sACE, containing an N-domain (blue) and C-
domain (maroon) and tACE (identical to the C-domain, maroon).  Transmembrane region 
(TM).
somatic promoter germinal promoter
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Figure 1.3.  Protein sequence alignment of sACE N- and C-domains, and tACE (adapted 
from Acharya et  al., 2003; Natesh et al., 2003; Corradi et  al., 2006).  Numbering and 
alignment according to that reported by Soubrier et al., (1988) and Ehlers et al., (1989).  The 
zinc-binding ligands and HEMGH motif are highlighted in purple and the chloride binding 
residues in green.  Active-site residues differing between domains are highlighted as follows: 
S2 orange, S1 yellow, S1’ pink, and S2’ in blue.  Bold residues indicate the sACE linker region 
between the N- and C-domains.
Although the two catalytic domains of ACE display  more than 60 % amino acid sequence 
identity  (figure 1.3), they  display some interesting differences.  For example, the chloride 
requirement for the C-domain is much higher than that of the N-domain (Wei et al., 1991; Wei 
et al., 1992), while the latter has been shown to be more thermally stable (Voronov et  al., 
2002; O'Neill et al., 2008).  Furthermore, a number of substrates have demonstrated C- or N-
sACE N-domain 1 ........LD    PGLQPGNFSA    DEAGAQLFAQ    SYNSSAEQVL    FQSVAASWAH
sACE C-domain 602        PLPD   NYPEGIDLVT    DEAEASKFVE    EYDRTSQVVW    NEYAEANWNY
tACE  20 TTTHQATAHQ    TSAQSPNLVT    DEAEASKFVE    EYDRTSQVVW    NEYAEANWNY
sACE N-domain 43 DTNITAENAR    RQEEAALLSQ    EFAEAWGQKA    KELYEPIWQN    FTDPQLRRII
sACE C-domain 646 NTNITTETSK    ILLQKNMQIA    NHTLKYGTQA    RKFDVNQLQN    TT...IKRII
tACE  70 NTNITTETSK    ILLQKNMQIA    NHTLKYGTQA    RKFDVNQLQN    TT...IKRII
sACE N-domain 93 GAVRTLGSAN    LPLAKRQQYN    ALLSNMSRIY    STAKVCLPNK    TATCWSLDPD
sACE C-domain 693 KKVQDLERAA    LPAQELEEYN    KILLDMETTY    SVATVCHPNG    ..SCLQLEPD
tACE  117 KKVQDLERAA    LPAQELEEYN    KILLDMETTY    SVATVCHPNG    ..SCLQLEPD
sACE N-domain 143 LTNILASSRS    YAMLLFAWEG    WHNAAGIPLK    PLYEDFTALS    PLYEDFTALS
sACE C-domain 741 LTNVMATSRK    YEDLLWAWEG    WRDKAGRAIL    QFYPKYVELI    NQAARLNGYV
tACE  165 LTNVMATSRK    YEDLLWAWEG    WRDKAGRAIL    QFYPKYVELI    NQAARLNGYV
sACE N-domain 193 DTGAYWRSWY    NSPTFEDDLE    HLYQQLEPLY    LNLHAFVRRA    LHRRYGDRYI
sACE C-domain 791 DAGDSWRSMY    ETPSLEQDLE    RLFQELQPLY    LNLHAYVRRA    LHRHYGAQHI
tACE  215 DAGDSWRSMY    ETPSLEQDLE    RLFQELQPLY    LNLHAYVRRA    LHRHYGAQHI
sACE N-domain 243 NLRGPIPAHL    LGDMWAQSWE    NIYDMVVPFP    DKPNLDVTST    MLQQGWNATH
sACE C-domain 841 NLEGPIPAHL    LGNMWAQTWS    NIYDLVVPFP    SAPSMDTTEA    MLKQGWTPRR
tACE  265 NLEGPIPAHL    LGNMWAQTWS    NIYDLVVPFP    SAPSMDTTEA    MLKQGWTPRR
sACE N-domain 293 MFRVAEEFFT    SLELSPMPPE    FWEGSMLEKP    ADGREVVCHA    SAWDFYNRKD
sACE C-domain 891 MFKEADDFFT    SLGLLPVPPE    FWNKSMLEKP    TDGREVVCHA    SAWDFYNGKD
tACE  315 MFKEADDFFT    SLGLLPVPPE    FWNKSMLEKP    TDGREVVCHA    SAWDFYNGKD
sACE N-domain 343 FRIKQCTRVT    MDQLSTVHHE    MGHIQYYLQY    KDLPVSLRRG    ANPGFHEAIG
sACE C-domain 941 FRIKQCTTVN    LEDLVVAHHE    MGHIQYFMQY    KDLPVALREG    ANPGFHEAIG
tACE  365 FRIKQCTTVN    LEDLVVAHHE    MGHIQYFMQY    KDLPVALREG    ANPGFHEAIG
sACE N-domain 393 DVLALSVSTP    EHLHKIGLLD    RVTNDTESDI    NYLLKMALEK    IAFLPFGYLV
sACE C-domain 991 DVLALSVSTP    KHLHSLNLLS    SEGGSDEHDI    NFLMKMALDK    IAFIPFSYLV
tACE  415 DVLALSVSTP    KHLHSLNLLS    SEGGSDEHDI    NFLMKMALDK    IAFIPFSYLV
sACE N-domain 443 DQWRWGVFSG    RTPPSRYNFD    WWYLRTKYQG    ICPPVTRNET    HFDAGAKFHV
sACE C-domain 1041 DQWRWRVFDG    SITKENYNQE    WWSLRLKYQG    LCPPVPRTQG    DFDPGAKFHI
tACE  465 DQWRWRVFDG    SITKENYNQE    WWSLRLKYQG    LCPPVPRTQG    DFDPGAKFHI
sACE N-domain 493 PNVTPYIRYF    VSFVLQFQFH    EALCKEAGYE    GPLHQCDIYR    STKAGAKLRK
sACE C-domain 1091 PSSVPYIRYF    VSFIIQFQFH    EALCQAAGHT    GPLHKCDIYQ    SKEAGQRLAT
tACE  515 PSSVPYIRYF    VSFIIQFQFH    EALCQAAGHT    GPLHKCDIYQ    SKEAGQRLAT
sACE N-domain 543 VLQAGSSRPW    QEVLKDMVGL    DALDAQPLLK    YFQPVTQWLQ    EQNQQNGEVL
sACE C-domain 1141 AMKLGFSRPW    PEAMQLITGQ    PNMSASAMLS    YFKPLLDWLR    TENELHGEKL
tACE  565 AMKLGFSRPW    PEAMQLITGQ    PNMSASAMLS    YFKPLLDWLR    TENELHGEKL
sACE N-domain 593 GWPEYQWHP.    ..........    ..........    ..........    ..........
sACE C-domain 1191 GWPQYNWTPN    SARSEGPLPD    SGRVSFLGLD    LDAQQARVGQ    WLLLFLGIAL
tACE  615 GWPQYNWTPN    SARSEGPLPD    SGRVSFLGLD    LDAQQARVGQ    WLLLFLGIAL
sACE N-domain  ..........    ..........    ..........    .......
sACE C-domain 1241 LVATLGLSQR    LFSIRHRSLH    RHSHGPQFGS    EVELRHS
tACE  665 LVATLGLSQR    LFSIRHRSLH    RHSHGPQFGS    EVELRHS
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domain selectivity, and several inhibitors have been reported to be able to discriminate 
between the two domains with high degrees of selectivity (discussed below).
 
1.2.1 The structures of tACE and the N-domain
Due to the lack of structural data for ACE, inhibitors were originally designed based on the 
structure of carboxypeptidase A (CPA), an enzyme displaying similar catalytic activity  to 
ACE (Cushman et al., 1977).  Interestingly however, resolution of the tACE-lisinopril 
complex in 2003 revealed that this enzyme shares little structural similarity  to CPA, and in 
fact demonstrates a much higher resemblance to the core structures of neurolysin and 
Pyrococcus furiosus CPA, two enzymes with little sequence similarity  to ACE (Natesh et al., 
2003).
Testis ACE (protein data bank (PDB) code 1o86; figure 1.4a) is ellipsoid in shape, exhibiting 
dimensions of 72x57x48 angstroms (Å) (Natesh et al., 2003).  It  is made up of two sub-
domains separated by an active-site cavity that extends approximately 30 Å into the protein, 
and contains a number of ordered water molecules.  Three ! helices, consisting of a number of 
charged amino acids, form an N-terminal lid region over the entrance to the active-site, 
limiting access to only smaller polypeptides.  The overall structural architecture is mostly 
helical with 27 helices throughout the protein.  The structure contains minimal beta structures. 
Six glycosylation sites occur on the surface of the enzyme, with a seventh site found within 
the transmembrane region.
The highly ordered catalytic zinc ion (figure 1.4), critical to catalysis, is bound to the active-
site by four ligands:  two histidines, H383 and H387 (tACE numbering; C-domain numbering 
959 and 963) from the HEXXH zinc-binding motif on helix 13, E411 (C-domain 987) situated 
on helix 14, and an acetate ion provided by the crystallisation medium (Natesh et al., 2003).
The activity of tACE and the C-domain of sACE is highly dependent on the concentration of 
chloride ions.  The tACE crystal structure revealed that two chloride ions are bound to tACE, 
chloride I and II, 20.7 and 10.4 Å from the zinc ion respectively (figure 1.4) (Natesh et al., 
2003), both buried away from the active-site, 20.3 Å apart.  Recent work by Rushworth et al. 
(Rushworth et al., 2008) has provided compelling evidence for the involvement of a number 
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of residues in the chloride sensitivity displayed by  ACE.  Mutation of the chloride I site 
chloride ion co-ordinating ligands, R186, R489 and W279, as well as the chloride II site 
chloride ligand R522, resulted in a marked decrease in the chloride dependence of tACE 
(Rushworth et al., 2008).  Although the location of the chloride ions does not indicate direct 
interaction with the substrate, the main ligand co-ordinating chloride II, R522, is situated on 
the same helix as Y520 and Y523 (C-domain Tyr’s 1096 and 1099), two residues involved in 
inhibitor (and probably  substrate) interaction.  It has been suggested that binding of a chloride 
ion to this site could facilitate movement of the Y523 into the active-site, and therefore 
binding at this site is believed to play  a role in catalysis (Tzakos et  al., 2003; Rushworth et al., 
2008).
Figure 1.4.  Three-dimensional structures of the ACE domains.  a) The tACE-lisinopril 
complex (taken from Natesh et al., 2003).  Each sub-domain is represented in cyan and pink, 
with the zinc and chloride ions highlighted in green and red, respectively.  Lisinopril (yellow) 
is bound to the active-site of tACE.  b) Alignment of the tACE (pink) and sACE N-domain 
(blue) 3-dimensional structures (taken from Corradi et al., 2006), with the zinc ion highlighted 
in green.
The crystal structure of the N-domain in complex with lisinopril was reported in 2006 (PDB 
code 2c6n; figure 1.4b) (Corradi et al., 2006).  Although the overall structure of the N-domain 
is similar to that of the C-domain, a number of differences were observed.  Ten glycosylation 
sites occur on the N-domain, of which only  three are conserved between domains. 
896 |  NOVEMBER 2003 | VOLUME 2 www.nature.com/reviews/drugdisc
R E V I EW S
Nevertheless, the use of CPA as a model led to key con-
ceptual insights in inhibitor design, because CPA was
much better understood and its crystal structure 
was known. Cushman and Ondetti reasoned that
ACE was an exopeptidase like CPA, with the difference
that ACE cleaved the penultimate peptide bond to
release a dipeptide product.
The second major breakthrough in inhibitor design
derived from an earlier observation that an extract from
the South American pit viper Bothrops jararaca, known
as bradykinin potentiating factor (BPF), could inhibit
ACE56–58. BPF was a mixture of peptides59, which were
shown to be potent and specific inhibitors of ACE
(TABLE 1), and structure–activity studies indicated that
the optimal C-terminal inhibitory sequence was Phe-
Ala-Pro60. This work led to the proposal that the venom
peptides were substrate analogues that bound competi-
tively to the obligatory substrate-binding sites in the
ACE active site (FIG. 5a). What was needed were orally
active, non-peptide analogues of BPF.
The third key insight derived from work by Byers and
Wolfenden61 describing a new design concept for
inhibitors of CPA based on benzylsuccinic acid, referred
to as by-product analogues. Cushman and Ondetti recog-
nized that part of the binding affinity of benzylsuccinic
acid derived from coordination of the active-site zinc by
the carboxyl group, and predicted that a similar succinyl-
amino acid derivative would inhibit ACE if its structure
was analogous to the dipeptide product of ACE activity.
On the basis of the Phe-Ala-Pro sequence derived from
the BPF peptides, they synthesized methylsuccinyl-Pro
(analogous to carboxy-Ala-Pro) and indeed found it to be
a specific inhibitor, with an IC50 of 22 µM53. Cushman
and Ondetti then searched for a superior zinc-binding
group and the potency breakthrough was achieved by
replacing the carboxyl with a sulphydryl group, yielding
captopril with an IC50 of 23 nM
53,54 (FIG. 5a).
Captopril became the first ACE inhibitor in clinical
use (first approved in 1981) and rapidly established itself
as a powerful new therapeutic agent in the treatment of
hypertension and heart failure. Reports of captopril-
related side effects, such as loss of taste and skin rash,
prompted Patchett and colleagues to focus on the design
of non-sulphydryl ACE inhibitors, by reverting to car-
boxyl compounds and introducing additional function-
alities that would complete the by-product design.
Captopril did not make use of at least two potential
binding sites: the S1 binding site and a hydrogen-bonding
site for the amide nitrogen of the (substrate) scissile
bond (FIG. 5a). So, structure–activity studies were per-
formed on a series of N-carboxyalkyl dipeptides of the
general formula R-CHCO2H-A1-A2. The R group, occu-
pying the S1 pocket, was best served by benzylmethylene,
whereas A1-A2 was either Ala-Pro (as in the BPF peptides)
or, surprisingly, Lys-Pro, leading to enalaprilat and
lisinopril, respectively (FIG. 5a)62, which show nanomolar
inhibition constants.
Enalaprilat and lisinopril are essentially tripeptide
analogues with a Zn2+-coordinating carboxyl group
substituting for the substrate scissile amide carbonyl.
Enalaprilat closely resembles the Phe-Ala-Pro sequence
First-generation ACE inhibitors
The story of the design and synthesis of the first orally
active, potent inhibitors of ACE is one of the great success
stories of modern medicinal chemistry. It has been
described as one of the first examples of true ‘rational
drug design’3, and although this might not be true in the
sense that we understand that term today, the design of
the ACE inhibitors in the late 1970s and early 1980s was
certainly based on a series of brilliant insights that,
together with a sprinkling of serendipity, constituted
what might now be called ‘rational intuition’.
It is not our intention to provide a comprehensive
review of the events leading to the design and synthesis
of captopril, enalaprilat and lisinopril, the original
group of potent ACE inhibitors that formed the basis for
all subsequent compounds of what can now be termed
first-generation ACE inhibitors. Several excellent
reviews of this history have been published during the
past two decades, especially by the inventors them-
selves45–50. However, it is instructive to consider some of
the key insights that led to these drugs, especially in the
context of the crystal structure that is now available and
the structure-guided drug design of second-generation
ACE inhibitors that can now be undertaken.
A role for a metal in the catalytic mechanism had
been suspected since the discovery of the enzyme16 and
was confirmed in the 1970s51,52, leading to the proposal
that ACE was mechanistically similar to carboxypepti-
dase A (CPA)53,54. We now know that ACE is unrelated
to the CPA class of enzymes, but instead falls into the
group of metallo-endopeptidases characterized by the
HEXXH zinc-binding motif55 (CPA possesses HXXE).
N
I
C
II
Cl2
Cl1
Zn
Figure 3 | Overview of the tACE structure5. The molecule
can be divided into two halves, sub-domains I and II (shown in
cyan and pink colour, respectively). The two bound chloride
ions are shown in r d. The catalytic site zinc ion and the
inhibitor lisinopril molecule are shown in green and yellow,
respectively. tACE, testis angiotensin-converting enzyme.
Figure 1. (a) The organisation of the different protein domains of the two isoforms of ACE, somatic ACE (sACE) and
testis ACE (tACE). The two catalytic domains of sACE each contain the HEXXH zinc-bindingmotif and are connected by
a short linker region (LR). Both forms comprise C-terminal juxtamembrane, transmembrane (TM), and cytosolic (CT)
domains. (b) Overall structure of the N domain with the zinc ion in green, the chloride ion in red and the sugars in green.
The N terminus and the inter-domain linker are shown in pink. Helices are numbered sequentially whether a or 310
using the letter H. (c) Superposition of the N domain (blue) and tACE (pink) with the zinc ion in green. (d) Backbone
coloured according to B factor with blue for the lowest B factors and red for the highest. The end of the inter-domain
linker and the “flexible loop” are i red. (e) Surface diagram showing the lid covering the central binding cavity (dark
blue), sugars (green) and the protruding surface patch (pink) comprising the linker nd t e flexible loop.
Structure f the N Domain of Human Somatic ACE 3
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Interestingly, only one chloride ion was bound to this domain corresponding to the chloride II 
site of tACE, consistent with the lowered dependence on chloride concentration observed in 
N-domain catalysis.  The site lacking a chloride ion, chloride I, contains a His residue 
replacing the corresponding Arg in tACE. 
Lisinopril binds similarly  to both active-sites (tACE and N-domain), in a highly ordered, 
extended conformation, with superimposition of the two complexes revealing conservation of 
inhibitor conformation as well as a number of conserved binding residue conformations 
(figure 1.5) (Natesh et al., 2003; Corradi et  al., 2006).  The binding of substrates and 
inhibitors to the catalytic site of ACE is commonly illustrated using the nomenclature model 
described by Schechter and Berger (Schechter and Berger, 1967).  Residues on the N-terminal 
side of the scissile bond (or zinc-binding group) are allocated P1-P2-P3-...-Pn, continuing 
outwards, while C-terminal residues are assigned P1’-P2’-P3’-...-Pn’.  The active-site to which 
the peptide or inhibitor binds is seen as a series of sub-site pockets into which the substrate or 
inhibitor residues or side-chains extend, and these pockets are designated with the 
corresponding Sn-...-S2-S1-S1’-S2’-...-Sn nomenclature.  
We can therefore describe the ACE active-site to consist  of four sub-sites, S2, S1, S1’ and S2’. 
The P1 phenylalanine of lisinopril extends into the S1 pocket, interacting favourably with the 
tACE residue V518 (C-domain 1094), replaced by T496 in the N-domain.  However, it has 
been suggested that the modest C-domain specificity observed for this inhibitor is due to the 
interaction of the P1’ lysine and the corresponding active-site pocket.  The structure of the N-
domain revealed a slightly  different backbone conformation for this side-chain compared to 
that within the tACE complex.  Furthermore, an electrostatic interaction between the lysyl 
amine and tACE E162 (C-domain 738) is lost in the N-domain, where the distance from the 
equivalent residue, D140, is 6.5 Å.  
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Figure 1.5.  Lisinopril bound to the active-site of ACE (adapted from Corradi et al., 2006). 
Stick representation of lisinopril (grey / pink for N-domain and tACE, respectively) and 
binding residues within the active-site of the N-domain (cyan) and tACE (pink).  Highlighted 
residues conserved between domains appear grey (tACE numbering).  The zinc and chloride 
II site ions are highlighted in green and red, respectively.
1.2.2 Mechanism of substrate hydrolysis
The catalytic mechanism of substrate hydrolysis has not yet been established for ACE. 
However, it has been suggested that the mechanism is similar to that proposed for another 
member of the gluzincin family (MA clan), thermolysin (Matthews, 1988; Pelmenschikov et 
al., 2002).
Catalysis of thermolysin takes place via a general base-type mechanism (figure 1.6) 
(Matthews, 1988).  It is believed that the incoming substrate displaces an active-site water 
molecule, bound to the zinc ion, towards a proximal glutamate residue, E143.  This 
displacement sets up the water molecule for nucleophilic attack on the carbonyl carbon of the 
peptide, to produce a tetrahedral penta-co-ordinated carbonyl carbon intermediate. 
Subsequent breakdown of this intermediate occurs to yield the products.
specific binding to the N-terminal groups of
RXP407, are Tyr369, Arg381 and Thr496 (Phe391,
Glu403 and Val518 in tACE) (Figure 3(b)).
A common arginine, Arg500 in the N domain,
which forms part of the chloride-binding site, is
another candidate for RXP407 interaction. In our
structure, although Arg500 is pointing towards
subsite S2, Arg381 is poi ting away from the subsit
in the lisinopril structure and molecule B of the
native structure. However, in molecule A of the
native structure Arg500 points towards the active
site, showing that this conformation is also possible.
Tyr369 also points towards the binding site and is
observed to have a patch of difference density
adjacent to it in both the native and lisinopril-
complex structures. In both cases, this was mod-
elled as water. As the inhibitor has both a charged
and polar moiety, it is possible that both arginine
residues (381 and 500), plus either the tyrosine or
the threonine, interact with the inhibitor.
The S2 0 subsite also has several differences
between the N and C domains, of which the
charged residues are located at the far end of the
cavity. This suggests an elongated conformation for
the inhibitor if the C-terminal amide is a determi-
nant for specificity, although the position of Ser357
and Thr358 on helix 15, provide a more polar
environment than the two valine residues present in
the C domain and may also contribute to the
appropriate binding cavity for RXP407
(Figure 3(b)).
These subsite changes are also likely to play a role
in the enzyme’s specificity for N domain substrates.
The case is more complex here, however, as N
domain specific substrates such as AcSDKP, Ang1-7
and Met5-Enk-Arg6-Phe7 also bind the C domain,
but are hydrolysed much less efficiently. This
suggests that specific determinants are responsible
for positioning for optimal catalysis rather than just
“tight binding”. In the case of these substrates, the
Figure 3. (a) Clos up of the ac ive site of the N omain (blue/green) an tACE (pink) with the zinc ion in green and
the conserved chloride ion in red. Lisinopril is shown in grey/pink for the N domain/tACE, respectively. The lisinopril
binding residues are shown in ball and stick. Residues common between the N domain and tACE are in grey (N domain
numbering) with differing residues for these two proteins shown in blue/green and pink, respectively. (b) A different
orientation of the native N domain active site (blue/green) with RXP407 (grey) approximately positioned using
mol cular docking. Residues differing between the N domain and tACE (equivalent to the C domain) in the S2 0 and S2
subsites and the chloride coordinating residues are shown in ball and stick. Residues conserved between the N domain
and tACE are shown in grey (N domain numbering), N domain residues are shown in blue/green and tACE residues in
pink. The chloride ion is shown in red.
Table 2. Active site residues that differ between the N and C domains (C domain numbering is as for tACE)
S2 tACE/C domain E403 F391 V518
N domain R381 Y369 T496
S1 tACE/C domain V518 S516 E143
N domain T496 N494 S119
S1 0 tACE/C domain E162 N277 S284 E372 N374 E376 D377 V380
N domain D140 D255 E262 R350 T352 D354 N355 T358
S2 0 tACE/C domain T282 S284 E376 V379 V380 D453
N domain S260 D262 D354 S357 T358 E431
6 Structure of the N Domain of Human Somatic ACE
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Figure 1.6.  The proposed mechanism of thermolysin substrate hydrolysis (taken from 
Matthews, 1988).   
A number of active-site residues crucial to ACE catalysis have been identified through site-
directed mutagenesis and the resolution of the crystal structure.  As mentioned above (section 
1.2.1), the zinc-coordinating ligands comprise two His residues (383 and 387 in tACE) and 
E384 (tACE) (Wei et al., 1991; Williams et al., 1994).  E384 (C-domain Glu 960) most likely 
corresponds to the E143 residue in thermolysin, while H513 (C-domain 1089) has been 
suggested to play a role in stabilising the transition state (Fernandez et al., 2001).  Other tACE 
residues that have been implicated to play a role in stabilising the transition state are K511 
and Y520 (C-domain 1087 and 1096, respectively) (Natesh et al., 2003).
1.2.3 ACE substrates
ACE is best known for its C-terminal dicarboxypeptidase activity, converting Ang I to Ang II 
and degrading BK (figure 1.7) (Skeggs et al., 1956; Erdos and Yang, 1967).  However, the 
promiscuity of this enzyme has implicated it in a number of other physiological processes. 
Furthermore, this enzyme has been found to possess an endopeptidase-like activity  on 
substrates containing amidated C-termini (Skidgel and Erdös, 1985).  As mentioned in the 
preceding sections, the two domains display  a number of differences, such as substrate 
selectivity (discussed below), chloride dependence (Wei et al., 1991; Wei et al., 1992) and 
thermostability (Voronov et al., 2002; O'Neill et al., 2008).
While the affinity  of Ang I is roughly equal for both the C- and N-domains of ACE, 
hydrolysis of this substrate is performed more efficiently by the C-domain’s active-site (Wei 
et al., 1991).  BK is cleaved approximately  10 times more efficiently than Ang I, and cleavage 
is non-specific between the C- and N-domains (Jaspard et al., 1993).  The C-domain is more 
dependent on chloride concentration than the N-domain (Wei et al., 1991), and this 
336 Matthews Accounts of Chemical Research 
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Figure 3. Proposed mechanism for the thermolysin-catalyzed cleavage f peptides (after ref 41).
pair of hydrogen bonds is analogous to the "oxyanion 
hole" of the serine proteases.46 The second oxygen of 
the hydrated peptide is also stabilized by interaction 
with the zinc as well as a strong hydrogen bond with 
Glu 143. The side-chain oxygen of Asn 112 and the 
backbone carbonyl of Ala 113 accept hydrogen bonds 
from the doubly protonated te rahedral nitrogen f the 
scissile bond (Figure 3c). These interactions are best 
exemplified by carbobenzoxy-PheP-Leu- Ala (ZFPLA) 
(Figures 4, 5b),24*25 an extremely tight-binding inhibitor 
of thermolysin (Ki = 0.068 nm)24 which is presumed to 
be a direct analogue of the tetrahedral intermediate (see 
also Figure 2a,f). The collapse of this intermediate 
(Figure 3c) to products (Figure 3d) is presumed to be 
facilitated by a second proton transfer via Glu 143 (not 
shown in Figure 3). In this case the proton is accepted 
from the hydrated peptide and shuttled to the leaving 
nitrogen.41 The recent determination of the complex 
of Val-Trp with th rmoly~in'~ provides a direct model
for the binding of the amine product of peptide hy- 
drolysis and suggests that the newly formed amino 
group interacts with the enzyme as illustrated in Figure 
3d. The mode of interaction of the acidic product is less 
certain. 
The early suggestion that His 231 might act as a 
proton donor16~45~47 now seems unlikely. However, the 
evidence that His 231 must be in its protonated state 
for catalysis45 is consistent with the idea that this res- 
idue helps stabilize the transition state by donating a 
hydrogen bond to the hydrated peptide (Figure 3b). 
Thermolysin and Carboxypeptidase A 
Although the amino acid sequences and the overall 
tertiary structures of thermolysin and carboxypeptidase 
A48 are unrelated, the active sites of these two metal- 
lopeptidases have elements in c o m m ~ n . ~ ~ , ~ ~  Superpo- 
sition of one active site on the other shows that the 
position of Glu 270 of carboxypeptidase A relative to 
the zinc and to a bound dipeptide corresponds closely 
to that of Glu 143 of thermolysin. This close corre- 
spondence suggested that the chemical and stereo- 
chemical combination of the zinc ion plus the acid group 
(Glu 143 of thermolysin; Glu 270 of arb xyp ptidas ) 
(46) Robertus, J. D.; Kraut, J.; Alden, R. A,; Birktoft, J. J. Biochem- 
(47) Pangburn, M. K.; Walsh, K. A. Biochemistry 1975, 14, 4050. 
(48) Lipscomb, W. N.; Hartsuck, J. A.; Reeke, G. N., Jr.; Quiocho, F. 
A,; Bethge, P. H.; Ludwig, M. L.; Steitz, T. A.; Muirhead, H.; Coppola, 
J. C. Brookhauen Symp. Quant. Biol. 1968,21,24. Lipscomb, W. N. Acc. 
Chem. Res. 1982,15, 232. Lipscomb, W. N. Annu. Reu. Biochem. 1983, 
52, 17. 
istry 1972, 11, 4293. 
(49) Rees, D. C.; Lipscomb, W. N. J.  Mol. Biol. 1982, 160, 475. 
(50)  Kester, W. R.; Matthews, B. W. J .  Biol. Chem. 1977, 252, 7704. 
was vital to catalysis.50 In contrast, it was also found 
that His 231 of thermolysin and Tyr 248 of carboxy- 
peptidase A, the two groups presumed (at that time) 
to be proton donors, did not occupy similar positions. 
This structural mismatch led to the conclusion that 
there was no absolute requirement for the involvement 
of a hi idine or a tyrosine i  hydrolysis catalyzed by 
the zinc neutral  protease^.^' 
The above differences between the active sites of 
thermolysin and carboxypeptidase can be reconciled by 
p o ~ t u l a t i n g ~ ~  that the mechanism of peptide cleavage 
by carboxypeptidase is analogous to that proposed in 
Figure 3 for thermolysin. In the proposed carboxy- 
peptidase A mechanism33 (Figure 6), Glu 270 is pre- 
sumed to act in conjunction with the zinc to promote 
the attack of a water molecule on the carbonyl carbon 
(Figure 6b). Glu 270 is then assumed to shuttle two 
protons successively to the leaving nitrogen (Figure 
6c,d), analogous to the mechanistic scenario that has 
been described for thermolysin. The proposal that Glu 
270 of carboxypeptidase A acts as a general base has 
been considered for a long and is supported by 
evidence from kinetic isotope effects51 and from the 
analysis of intermediates by cryokinetic and cryospec- 
troscopic techniques52 (but see also ref 53). The ad- 
ditional proposal that Glu 270 rather than Tyr 248 acts 
as proton donor was not favored previously49 but has 
been supported by the demonstration that Tyr 248 of 
carboxypeptidase A can be replaced with phenylalanine 
with little effect on catalytic activity.54 The proposed 
mechanism33 has recently been supported by model 
studies55 and has been adopted by Lipscomb and co- 
w o r k e r ~ ~ ~  to rationalize the binding of substrate ana- 
logues to the crystalline enzyme. 
The similar mechanisms proposed for thermolysin 
(Figure 3) and carboxypeptidase A (Figure 6) are com- 
(51) Breslow, R.; Wernick, D. L. Proc. Natl. Acad. Sci. U.S.A. 1977, 
74, 1303. Breslow, R.; Chin, J.; Hilvert, D.; Trainor, G. Proc. Nutl. Acad. 
Sci. U.S.A. 1983,80, 4585. 
(52) Geoghegan, K. F.; Holmquist, B.; Spilburg, C. A.; Vallee, B. L. 
Bioche istry 1983,22, 1847. Galdes, A.; Auld, D. S.; Vallee, B. L. Bio- 
chemistry 1986, 25, 646. 
(53) There is good evidence that certain conjugated ester substrates 
of carboxypeptidase A are cleaved via the anhydride pathway. All ex- 
amples of this type reported to date are closely related to 0-(trans-p- 
chlorocinnamoy1)-L-phenyllactate. Makinen, M. W.; Kuo, L. C.; Dy- 
mowski, J.; Jaffer, S. J .  Biol. Chem. 1979, 254, 356. Kuo, L. C.; Fuku- 
yama, J. M.; Makinen, M. W. J .  Mol. Biol. 1983, 163, 63. Kuo, L. C.; 
Makinen, M. W. J .  Am. Chem. SOC. 1985, 107, 5255. Sander, M. E.; 
Witzel, H. Biochem. Biophys. Res. Commun. 1985, 132, 681. Suh, J.; 
Hong, S.-B.; Chung, S. J .  Biol. Chem. 1986, 261, 7112. 
(54) Gardell, S. J.; Craik, C. S.; Hilvert, D.; Urdea, M. S.; Rutter, W. 
J. Nature (London) 1985,317, 551. 
(55) Breslow, R.; Schepartz, A. Chem. Lett. 1987, 1. Schepartz, A,; 
Breslow, R. J .  Am. Chem. Sot. 1987, 109, 1814. 
(56) Christianson, D. W.; David, P. R.; Lipscomb, W. N. Proc. Natl. 
Acad. Sci. U.S.A. 1987, 84, 1512. 
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phenomenon is further dependent on the type of substrate concerned.  For example, Ang I 
cleavage is extremely chloride dependent, particularly  for the C-domain, whereas the absolute 
chloride requirement for BK hydrolysis by either domain is significantly lower (Jaspard et al., 
1993).
Figure 1.7.  Some physiological substrates of ACE.  The position of peptide bond cleavage 
is indicated with an arrow.  Pyroglutamic acid (pGlu); amidated C-termini (CONH2). 
To date, a variety of peptide substrates have been described for this enzyme, some of which 
display  interesting domain selectivity (figure 1.7).  N-acetyl-Ser-Asp-Lys-Pro (AcSDKP), a 
negative regulator of hematopoiesis, has been shown to be preferentially cleaved by the N-
domain of ACE, in vitro (Rousseau et al., 1995).  In vivo inhibition of this domain of ACE 
using RXP407 demonstrated an approximately 6-fold increase in AcSDKP levels in mice 
(Junot et al., 2001).  Other peptide substrates cleaved primarily  by  the N-domain include 
Ang(1-7) (Ehlers and Riordan, 1991; Deddish et  al., 1994) and gonadotropin-releasing 
hormone (GnRH) (formally  known as luteinizing-hormone releasing hormone) (Jaspard et al., 
1993).  The neuropeptide Substance P is preferentially cleaved by the C-domain of ACE, and 
this cleavage is dependent on the concentration of chloride (Jaspard et al., 1993).  The 
physiological relevance of this hydrolysis is not  yet clear, however both Substance P and ACE 
 
 
Ang I  H3N-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-COOH
 BK  H3N-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-COOH
 AcSDKP N-acetyl-Ser-Asp-Lys-Pro-COOH
 Ang(1-7) H3N-Asp-Arg-Val-Tyr-Ile-His-Pro-COOH
 GnRH pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-CONH2
 Substance P H3N-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-CONH2
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have been shown to co-localise to certain areas of the brain (Defendini et al., 1983; Matsas et 
al., 1984; Strittmatter et al., 1984; Oblin et al., 1988; Barnes et al., 1988).
A number of synthetic peptide substrates have been designed for the enzymatic 
characterisation of ACE.  The Ang I analogue hippuryl-His-Leu (HHL), is hydrolysed more 
efficiently by  the C-domain of ACE to release HL and hippurate, and displays a similar 
chloride dependence to that of Ang I (Friedland and Silverstein, 1976).  Z-Phe-His-Leu (Z-
FHL), a second Ang I analogue, contains a Phe in the P1 position which significantly 
decreases the selectivity  of this peptide resulting in equivalent cleavage by  both domains 
(Danilov et al., 1994; Michaud et al., 1997).  Another peptide design resulted in furylacryloyl-
Phe-Gly-Gly (FAPGG), cleavage of which by ACE yields the FAP tripeptide and GG 
dipeptide (Holmquist et al., 1979; Beneteau et al., 1986).  Interestingly, hydrolysis of this 
substrate is chloride-dependent (Baudin, 2002).
Another class of peptide substrates commonly used are the fluorescence resonance energy 
transfer (FRET) peptides (Yaron et  al., 1979).  These internally quenched peptides contain a 
fluorescent donor group  attached to the amino-terminal end, such as o-aminobenzoic acid 
(Abz), and a C-terminal quenching group (acceptor), such as 2,4-dinitrophenyl (Dnp) (Araujo 
et al., 1999).  Hydrolysis within the FRET peptide separates the donor-acceptor pair, resulting 
in an increase in fluorescence from basal levels.  A series of these peptides have been 
specifically designed for the analysis of ACE activity, and include the non-specific substrates 
Abz-FRK(Dnp)P-OH and Abz-YRK(Dnp)P-OH, the C-domain-specific Abz-LFK(Dnp)-OH 
and the N-domain-specific Abz-SDK(Dnp)P-OH (Araujo et al., 2000; Bersanetti et al., 2004).
1.2.4 ACE inhibitors
Due to the lack of any structural data for ACE, Cushman and Ondetti reasoned that the X-ray 
crystal structure of the distant homologue CPA should share a number of similarities with 
ACE (Skeggs et al., 1956; Cushman and Cheung, 1971; Das and Soffer, 1975).  For example, 
both relied on a metal ion for their catalysis and displayed C-terminal exopeptidase-like 
activity, although ACE cleaved a dipeptide, while CPA only cleaved a single residue.  Using 
the CPA structure (Steitz et al., 1967), they were able to develop a hypothetical prototype of 
the ACE active-site within which they could model potential inhibitors.  
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Another key step  in this process was the observation that certain peptides potentiating the 
action of BK, derived from the venom of Bothrops jararca, a South American pit viper, were 
able to specifically block ACE activity  (Ferreira et al., 1970).  Further analysis revealed that 
the most potent peptides specifically inhibiting ACE comprised the C-terminal sequence Phe-
Ala-Pro (Ondetti et al., 1971).  The clinical use of these peptides was not however feasible as 
they  lacked oral activity, and it was with the third key insight that led to a series of orally 
active ACE inhibitors.  
A new and potent CPA inhibitor, benzylsuccinic acid, described as a by-product  analogue 
(Byers and Wolfenden, 1973), presented a new design concept incorporating a strong active-
site zinc co-ordinating group, as well as side-chain interactions analogous to those of the 
peptide product within the catalytic site.  Cushman and Ondetti then synthesised the carboxy-
Ala-Pro analogue, methylsuccinyl-Pro, which proved to be a specific ACE inhibitor but with 
low potency  (Cushman et al., 1977).  This potency was subsequently  increased 1000-fold by 
substituting the carboxyl group with a superior zinc-binding sulphydryl group (Ondetti et al., 
1977), producing captopril (figure 1.8), the first orally active ACE inhibitor approved for 
clinical use in the treatment of hypertension and heart failure.
Captopril did however display a number of side-effects such as loss of taste, dry cough and 
skin rash (McNeil et al., 1979), and this motivated further development of non-sulphydryl 
ACE inhibitors.  Patchett et al. observed that captopril did not take advantage of interactions 
within the S1 pocket, and lacked the hydrogen bond donor usually provided by  the amide 
nitrogen in the scissile bond of a substrate (Patchett et al., 1980).  They  screened a library  of 
N-carboxyalkyl dipeptides with the general formula R-CHCO2H-X1-X2 and found that a 
benzylmethylene substituent in the P1 position (R group), along with the dipeptides Ala-Pro or 
Lys-Pro (enalaprilat and lisinopril, respectively), yielded compounds that specifically 
inhibited ACE at nanomolar concentrations (figure 1.8) (Patchett et al., 1980).  
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Figure 1.8.  Some well-known ACE inhibitors.
Since the development of captopril, enalaprilat and lisinopril, a broad range of ACE inhibitors 
have been described, some of which are in clinical use today  (Zaman et al., 2002).  More 
recently, a number of inhibitors able to discriminate specifically between the two domains of 
ACE have been described.  The phosphinic peptide inhibitors RXP407 and RXPA380 (figure 
1.8) are able to selectively inhibit the N- and C-domains of ACE by three orders of 
magnitude, respectively  (Dive et al., 1999; Georgiadis et al., 2003).  Furthermore, the keto-
ACE derivatives (figure 1.8) (5S)-5-[(N-benzoyl)-amino]-4-oxo-6-phenyl-hexanoyl-L-
tryptophan (kAW) and (5S)-5-[(N-benzoyl)-amino]-4-oxo-6-phenyl-hexanoyl-L-
phenylalanine (kAF) containing a Trp  and a Phe in the P2’ position, respectively, both 
demonstrated C-domain selectivity  (Redelinghuys et  al., 2006).  Moreover, lisinopril-Trp  (lis-
W) (figure 1.8), a lisinopril analogue containing a Trp in the P2’ position, was able to 
selectively inhibit the C-domain (Nchinda et al., 2006a).
Non-domain-selective inhibitors
Domain-selective inhibitors
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1.3 Comparison of ACE with other two domain homologues 
The occurrence of two homologous active-sites in one polypeptide chain is a rare 
phenomenon, thought to come about by gene duplication leading to the evolutionary 
development of new activities by  modification and co-operativity  (Bergdoll et al., 1998; Díaz-
Mejía et al., 2007).
Two well-studied enzymes that also contain two catalytic sites on one polypeptide chain are 
sucrase-isomaltase (Hunziker et al., 1986) and lactase-phlorizin hydrolase (LPH) (Mantei et 
al., 1988), both involved in sugar metabolism on the brush-border membrane of the small 
intestine.  The sucrase and isomaltase domains of sucrase-isomaltase are 40 % identical, with 
a further 41 % sequence similarity  in non-identical amino acids.  Each domain contains a 
conserved active-site aspartic acid residue, and like ACE, sequence similarity between 
domains increases substantially  within the active-site.  The precursor of this complex 
(prosucrase-isomaltase) is synthesised as a single polypeptide chain, and is cleaved 
extracellularly by  pancreatic trypsin into two subunits, which remain strongly  associated by 
non-covalent, ionic interactions.  Jacob et al. (Jacob et al., 2002), have shown that the folding 
of the C-terminal sucrase domain is independent of the N-terminal isomaltase domain of the 
complex, and that the sucrase domain acts as an intramolecular chaperone for folding of the 
isomaltase subunit. 
The precursor form of LPH comprises four 38 - 55 % homologous domains (I – IV, of which 
only regions III and IV, each containing a conserved catalytic glutamine, are present in the 
mature enzyme (Mantei et al., 1988).  The lactase domain is responsible for the degradation of 
lactose, while the phlorizin hydrolase domain participates in the metabolism of #-
glycoceramides, however the domain assignment of each of these activities to a particular 
region has been debated (Zecca et al., 1998).  In 2000, Arribas et al. (Arribas et  al., 2000) 
settled this issue using selective, mechanism-based inhibitors, assigning lactase activity  to 
region IV, while phlorizin activity was allocated to region III.  Although these homologous 
domains are similar, like ACE, they have demonstrated a number of differences such as 
temperature dependence (Schlegel-Haueter et  al., 1972; Kraml et al., 1972; Colombo et al., 
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1973; Skovbjerg et  al., 1981).  Interestingly, Beau et al.  (Beau et al., 2007) have recently 
shown that rotaviruses, highly  pathogenic agents with multiple mechanisms through which 
they  induce diarrhoea, can affect the activity  of LPH, and reported that a secreted rotaviral 
protein, NSP4, specifically inhibits the lactase activity of LPH.
Human carboxypeptidase D (CPD) has been reported to have a broad tissue distribution, with 
increased levels within the trans Golgi network and immature secretory vesicles (Song and 
Fricker, 1995; Song and Fricker, 1996; Tan et al., 1997).  It  contains three extracellular 
domains on a single polypeptide chain (Song and Fricker, 1995; Tan et al., 1997).  The third 
domain (domain III) is catalytically inactive, and believed to be involved in binding proteins 
(Eng et al., 1998; Novikova et al., 1999).  The first two catalytic domains cleave C-terminal 
residues presumably  from the products of endopeptidases co-localised with CPD, such as 
furin (Seidah et al., 1992; Schäfer et al., 1993; Seidah et al., 1994; Zheng et al., 1994; Song 
and Fricker, 1996; Seidah et al., 1996).  Although similar, these two domains have displayed 
some interesting, complementary differences (Novikova et al., 1999).  
Of particular physiological interest, the pH optima and substrate selectivity of each is 
different (Novikova et al., 1999).  The first domain (domain I) has an approximately neutral 
pH optimum of 6.3-7.5, consistent with being active in regions such as the Golgi and 
extracellular environment, while the second site (domain II) performs most efficiently in a 
slightly acidic medium (5.0-6.5), and is therefore probably the dominant domain in the trans 
Golgi network and immature and mature secretory vesicles (Johnson and Scarpa, 1976; 
Russell, 1984; Novikova et al., 1999).  While both domains show a preference for an Ala 
residue in the penultimate position, the first and second domains respectively cleave C-
terminal Lys or Arg amino acids more efficiently (Novikova et al., 1999).  
A basis for the selectivity within these S1 and S1’ pockets can be provided by  crystallographic 
data reported for the second domain (Gomis-Rüth et al., 1999), as well as sequence and 
structural alignment of this domain to the first (figure 1.9) (Kuroki et  al., 1995; Aloy  et al., 
2001).  Residues surrounding the S1 pocket are highly conserved between the two domains 
(Gomis-Rüth et  al., 1999; Aloy et al., 2001).  W748 dramatically  reduces the size of this 
pocket thereby facilitating the preference for Ala residues in this position (figure 1.10).  The 
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conserved D691 (D271 in domain I) provides the highly  negative environment favouring the 
presence of positive residues in the C-terminal position of the substrate (figure 1.10).  The 
higher selectivity for Lys and Arg by the first and second domains, respectively, is probably 
due to the larger space available within the S1’ pocket of the second domain.  This larger 
space is a result of the respective substitution of Glu and Ile (335 and 351, respectively) in the 
first domain by the smaller residues P752 and V768 in the second domain (figure 1.10).
Figure 1.9.  Structural  alignment of the crystal structure of CPD domain II (PDB code 
1h8l) to the model of CPD domain I (taken from Aloy et al., 2001).one being bound in a bidentate manner by one of the carboxy-
late groups of the inhibitor. In addition, the inhibitor is bound
to residues of CPD-II that are essential for substrate binding
and polarization, Tyr250, Arg145, and Arg135. Therefore, several
structural elements indispensable for the catalytic action of the
enzyme are perturbed or shielded by the inhibitor.
Taking into account the similarity of CPD-II to the modeled
structures and the easy way in which GEMSA has been fitted
on them, it is expected that the inhibitor binds in a very similar
way to CPD-I and CPE. However, it is unlikely that GEMSA
binds CPD-III because of the absence of critical residues (dis-
cussed below).
Overall Comparison of the Models—The derived models of
CPD-I, CPD-III, and CPE show an overall similarity with the
recently described crystal structure of CPD-II (32). In all mod-
els two subdomains are clearly visible, the CP subdomain and
the C-terminal subdomain, which shares topological similarity
and connectivity with transthyretin (32). The CP subdomain
shows the !/"-hydrolase fold common to many proteases from
the cysteine, serine, and metalloprotease families. It is formed
by a doubly wound eight-stranded "-sheet flanked on both
sides by three and six helices, respectively. Meanwhile, the
C-terminal subdomain displays a rod-like shape forming a
"-barrel or "-sandwich of pre-albumin-like folding topology
made up by seven strands connected by short loops. This is
valid for all the models studied here.
As in CPD-II, the interactions between both subdomains are
mainly of a hydrophobic nature in all models. Most of the van
der Waals’ interactions described for CPD-II are also found in
CPD-I and CPE. Albeit containing a smaller number of such
interactions, CPD-III still conserves the most significant ones.
A number of hydrogen bonds also contribute to subdomain
interactions in CPD-I, CPD-III, and CPE, most of them being
exactly conserved in CPD-I and CPE versus CPD-II, and
greater differences being found for CPD-III. It is worth men-
tioning that the only salt bridge between subdomains described
for CPD-II, Asp206–Arg343, is also conserved in the modeled
structures between pairs of Asp/Arg at equivalent positions in
CPD-I and CPE and between Glu1123 and His1258 at equivalent
positions in CPD-III. Also, the disulfide bond in CPD-II be-
tween Cys230 and Cys275 is also predicted in the three models;
an additional disulfide between Cys70 and Cys132 in CPE (al-
ready detected from biochemical measurements) is also pre-
dicted in the model built for this form.
CPE is the protein with the highest homology to CPD-II and
also the one whose model has the lowest RMSD value with the
experimental 3D structure. However, it should be taken into
account that the RMSD value was calculated only on the struc-
turally equivalent residues given by the alignment performed
with the program SSAP. This means, for instance, that the
23-residues insertion in CPE, spanning from Glu158 to Lys189,
was not considered. As compared with CPD-II, pancreatic and
bacterial CPs also have a 14-amino acid insertion in this re-
gion, forming a loop that shapes one side of the entrance to the
active site and establishing cross-connections to an adjacent
loop. This feature is considered to be one of the distinctive
determinants of specificity between regulatory and pancreatic
CPs. The 23 extra residues in CPE form a turn-rich region
rather exposed to the solvent in the model built, according to
the well defined structure of this loop in Thermoactinomyces
vulgaris CPT (1obr).
The main difference between CPD-I and CPD-II is the above
mentioned long insertion of 29 residues in CPD-I that contains
20 net charges. This sequence was eliminated from the calcu-
lations as no homologous sequences and 3D structures were
found to model it with a sufficient degree of confidence. A
further significant difference is a glycine-rich insertion of nine
residues in one of the loops that shape the active site entrance
(residues 165 to 173 in Fig. 1). This insertion does not generate
a substantial change in the surface of the active site cleft in our
model and is folded inwards over the molecular body of the
enzyme.
The study of the model of CPD-III is particularly important
because of its lack of enzymatic activity (31), probably because
of the absence of key residues for CP catalysis. However, align-
ment of the sequences and superimposition of the 3D struc-
tures shows that other residues with yet unknown function are
highly conserved. When comparing the models and the struc-
ture, three categories of residues can be defined. The first one
is formed by the residues essential for catalysis. In CPD-II,
these essential residues are His74, Glu77, and His181 (coordina-
tors of Zn2!), Glu272, and Arg135. Only the first His is conserved
in CPD-III, whereas the other residues are replaced by Ala,
Asp, Tyr, and His, respectively. The enzymatic machinery of
CPD-III is therefore disabled, because neither proper coordina-
tors of Zn2! nor a general base or a polarizing residue are
present (6), respectively.
Those residues that are necessary for substrate binding are
FIG. 4. Ribbon representation of
the modeled structures of duck CPD
(domains I and III) and human CPE,
compared with the crystal structure
of duck CPD II. Top, the three loops that
shape the entrance to the active site are
in red (124–134), green (149–158), and
cyan (225–241). Bottom, modeled struc-
tures showing the regular secondary
structures, !-helix (blue) and "-strands
(magenta). The residue numbering corre-
sponds to the CPD-II structure.
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Figure 1.10.  Stick representation of the CPD inhibitor GEMSA (orange carbons) 
complexed to the active-site of domain II of CPD (PDB code 1h8l) (Aloy et al., 2001). 
Residues of interest  are indicated in green carbons, labelled as domain II / domain I.  The 
active-site zinc ion is represented as a grey sphere and two zinc-chelating residues are shown as black 
lines (H573 and H680).  This image were created in MacPyMOL version 0.99 (DeLano Scientific, 
Palo Alto, CA, USA).
A wide variety of neuroendocrine peptide products released by  enzymes such as 
endopeptidases and carboxypeptidases, require further post-translational modification for full 
biological activity  (Mains et al., 1990; Dickerson and Noel, 1991; Steiner, 1991; Jung and 
Scheller, 1991; Eipper et al., 1992).  Sequential activity of the bifunctional peptidylglycine !-
amidating monooxygenase (PAM), is responsible for !-amidation of a number of these 
bioactive peptides.  The peptidyl-!-hydroxyglycine intermediate is produced from glycine-
extended peptides, by  the action of the first PAM domain, peptidylglycine !-hydroxylating 
monooxygenase (PHM), which requires the co-factors copper, molecular oxygen and 
ascorbate (Eipper et al., 1992).  The second component of PAM, peptidyl-!-hydroyglycine !-
amidating lyase (PAL), converts this intermediate into a peptide containing an !-amide, and a 
glyoxylate (Katopodis et al., 1990; Suzuki et al., 1990; Katopodis et al., 1991).  Interestingly, 
PAM has a number of gene products, all transcribed from a single gene spanning 
approximately 160 kb of deoxyribonucleic acid (DNA) (Kato et  al., 1990; Ouafik et al., 
V768/I269
D691/D271
P752/E335
W748/W331
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1992).  This large size is mostly due to four unusually  long introns occurring within the PHM 
section of the gene. 
In all of the homologous enzymes discussed above, a few active-site substitutions results in 
notably dissimilar functions, which are often interestingly complementary.  In contrast with 
these examples, ACE exhibits a broad substrate selectivity, with each domain able to 
hydrolyse a wide range of substrates.  However, as mentioned above, these domains have 
demonstrated a number of differences.
1.4 Domain selectivity of ACE
1.4.1 Rationale for domain-selective ACE inhibitor therapies
It is clear, as motivated above, that the RAS provides a number of excellent  targets for anti-
hypertensive therapy.  Many agents are routinely used to interrupt this system at multiple 
stages.  These include ACE (Waeber et al., 1982) and renin (Wood et al., 2003) inhibitors, and 
AT1 (Ruilope et al., 2005) and aldosterone (Ménard, 2004) receptor blockers.  Other 
therapeutic drugs commonly used for the treatment of this condition are beta blockers, 
calcium channel blockers, alpha blockers and diuretics (Cushman, 2003).  All of these 
treatments, however, have high dosing, with a number of side-effects.
There is a wide range of clinical ACE inhibitor therapies currently  used for the treatment of a 
number of cardiovascular related conditions, such as hypertension and heart failure (Bicket, 
2002; Sleight, 2002).  All of these agents demonstrate modest, if any, selectivity between the 
two domains of this enzyme (Menard and Patchett, 2001), and although they are generally 
well tolerated, they have been associated with a number of adverse side-effects, such as a 
persistent dry  cough (5 - 20 % of cases) and the potentially fatal angioedema (0.1 - 0.5 % of 
cases) (Bicket, 2002; Adam et al., 2002; Dickstein et al., 2002; Morimoto et  al., 2004).  Both 
of these side-effects have been attributed to the resulting excess levels of BK caused by  the 
non-selective inhibition of both domains with these therapies (Semple, 1995; Lalloo et  al., 
1996).  It is important to mention that two non-domain-selective ACE inhibitors currently in 
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use for the treatment of cardiovascular conditions, Perindopril and Imidapril, have been 
shown to display significantly lowered side-effects, such as cough (Saruta et al., 1999; Huang 
et al., 2001; Tumanan-Mendoza et al., 2007).  Therefore, the exact mechanism behind ACE 
inhibitor related side-effects is still not  clear.  However, a recent study comparing the effects 
of these inhibitors to two other commonly used ACE inhibitor therapies, Cilazapril and 
Enalapril, found that these lowered side-effects also resulted in a lowered control of 
hypertension over the latter treatments which demonstrated more efficient management of 
hypertension (Tumanan-Mendoza et al., 2007).  
A number of studies investigating the role of each domain of ACE in Ang I and BK 
metabolism have been performed.  The results of most of this work appear to indicate that 
while both domains contribute equally  to BK degradation and soluble Ang I conversion, the 
C-domain seems to be primarily responsible for the systemic production of Ang II (Junot et 
al., 2001; Fuchs et al., 2004; van Esch et  al., 2005; Fuchs et al., 2008).  Support for this theory 
is provided by two studies involving the N- and C-domain-selective inhibitors RXP407 and 
RXPA380, respectively.  While N-domain-selective inhibition by RXP407 decreased 
AcSDKP levels in mice by approximately 6-fold, it was unable to block the pressor action of 
Ang I injections, whereas lisinopril prevented the blood pressure increase observed in the 
absence of inhibitor (Junot et al., 2001).  Further investigation by van Esch et al. involved 
analysis of Ang I metabolism in soluble versus membrane-bound ACE (van Esch et al., 2005). 
By examining the effect of RXPA380 and RXP407 on Ang I-induced contractions of porcine 
femoral arteries, they  discovered that  C-domain-selective inhibition was sufficient to block 
these contractions, while selective N-domain inhibition had no effect.  The inhibition of both 
domains was however required to prevent Ang II production from Ang I added to diluted 
human plasma.  Moreover, complete blockage of BK degradation was only achieved with the 
simultaneous inhibition of both domains of ACE (Georgiadis et al., 2003; van Esch et al., 
2005).
A number of transgenic mouse models have been instrumental in gaining better insight into 
the physiological roles of ACE.  Animals completely lacking both the somatic and germinal 
isoforms of this enzyme have presented with a number of phenotypes.  Among these are 
hypotension, decreased male fertility, and structural and functional renal defects (Krege et al., 
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1995; Esther et al., 1996; Tian et al., 1997; Cole et al., 2000).  Later, more elegant studies 
involving mice containing a fully  intact C-domain and inactivated N-domain (Fuchs et  al., 
2004), demonstrated that the presence of the C-domain restored blood pressure and normal 
renal development.  Analysis of renin, Ang I and Ang II peptides confirmed equivalent levels 
to those of wild-type animals. 
More recently, a similar mouse model was developed in which the sACE gene contains a 
catalytically  active N-domain, but the C-domain and tACE isoforms were inactivated (Fuchs 
et al., 2008).  These animals presented with normal blood pressure and Ang II peptide levels. 
However, further investigation revealed that this blood pressure restoration was due to a 
significant increase in renin and Ang I levels.  The pressor response to Ang I infusion was half 
that of wild-type mice.
Taken together, these phosphinic inhibitor and transgenic mouse studies provide strong 
evidence that the C-domain alone is sufficient to maintain blood pressure and angiotensin 
metabolism, while the N-domain is much less efficient at Ang I cleavage.  Furthermore, single 
domain inhibition does not block the degradation of BK.  Therefore it is reasonable to propose 
that orally active C-domain-selective ACE inhibitors have the potential to effectively  lower 
hypertension by  blocking Ang II production, while displaying significantly lowered side-
effects associated with current  ACE inhibitor therapy, as the N-domain would be free to 
maintain BK levels (Georgiadis et al., 2003; Acharya et al., 2003). 
1.4.2 The molecular basis for domain selectivity of ACE
With access to the crystal structures of both the C- and N-domains in complex with a variety 
of ACE inhibitors, a number of research groups have been able to dock different C- and N-
domain-selective inhibitors within the active-sites of each domain.  Together, this work has 
implicated a number of residues within these sub-site pockets of ACE which could play a role 
in conferring the domain selectivity of ACE (table 1.1, and see figures 3.4, 3.5, 4.6 and 4.9). 
There has, however, been no work reporting mutagenesis of these residues and their effects on 
binding and catalysis.
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Table 1.1.  Summary of active-site residues implicated in domain selectivity. 
Pocket
tACE 
(C-domain) 
residue
N-domain 
residue Crystal structure References
S2 Phe 391 (967) Tyr 369 tACE-RXPA380 
(PDB code 2oc2)
Acharya et al., 2003; Redelinghuys et al., 
2005; Tzakos and Gerothanassis, 2005; 
Redelinghuys et al., 2006; Jullien et al., 
2006; Corradi et al., 2006; Corradi et al., 
2007.
Glu 403 (979) Arg 381
-
Acharya et al., 2003; Redelinghuys et al., 
2005; Tzakos and Gerothanassis, 2005; 
Redelinghuys et al., 2006; Jullien et al., 
2006; Corradi et al., 2006; Corradi et al., 
2007.
S1 Ser 516 (1092) Asn 494 - Bersanetti et al., 2004; Tzakos and Gerothanassis, 2005; Jullien et al., 2006.
Ser 517 (1093) Val 495 - Jullien et al., 2006.
Val 518 (1094) Thr 496 tACE-lisinopril
(PDB code 1o86)
N-domain-lisinopril
(PDB code 2c6n)
Acharya et al., 2003; Natesh et al., 2003; 
Natesh et al., 2004; Bersanetti et al., 2004; 
Redelinghuys et al., 2005; Tzakos and 
Gerothanassis, 2005; Jullien et al., 2006.
S1’ Glu 162 (738) Asp 140 tACE-lisinopril
(PDB code 1o86)
N-domain-lisinopril
(PDB code 2c6n)
Natesh et al., 2003; Natesh et al., 2004; 
Bersanetti et al., 2004; Redelinghuys et al., 
2005; Tzakos and Gerothanassis, 2005; 
Corradi et al., 2006.
Asp 377 (953) Gln 355 tACE-lisinopril
(PDB code 1o86)
N-domain-lisinopril
(PDB code 2c6n)
Natesh et al., 2003Natesh et al., 2004; 
Bersanetti et al., 2004; Redelinghuys et al., 
2005; Tzakos and Gerothanassis, 2005; 
Corradi et al., 2006.
S2’ Thr 282 (858) Ser 260 - Georgiadis et al., 2004; Bersanetti et al., 2004; Tzakos and Gerothanassis, 2005.
Glu 376 (952) Asp 354 - Georgiadis et al., 2004; Bersanetti et al., 
2004; Tzakos and Gerothanassis, 2005.
Val 379 (955) Ser 357 tACE-RXPA380 
(PDB code 2oc2)
Georgiadis et al., 2004; Bersanetti et al., 
2004; Tzakos and Gerothanassis, 2005; 
Corradi et al., 2007.
Val 380 (956) Thr 358 tACE-RXPA380 
(PDB code 2oc2)
Georgiadis et al., 2004; Bersanetti et al., 
2004; Tzakos and Gerothanassis, 2005; 
Corradi et al., 2007.
Asp 453 (1029) Glu 431 tACE-RXPA380 
(PDB code 2oc2)
Georgiadis et al., 2004; Bersanetti et al., 
2004; Tzakos and Gerothanassis, 2005; 
Corradi et al., 2007.
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1.4.2.1 The S2 pocket
A number of structure-activity studies have indicated that N-selectivity seems to be enhanced 
with the presence of an acidic group in the P2 position, as in the case of RXP407 (Dive et al., 
1999), while substitution of this moiety with a large uncharged or basic side-chain seems to 
favour the C-domain S2 sub-site (Acharya et al., 2003).  Both F391 and E403 (tACE 
numbering), replaced by Tyr and Arg in the N-domain (table 1.1), have been identified as 
residues that may play a role in domain selectivity of some inhibitors (Redelinghuys et al., 
2005; Tzakos and Gerothanassis, 2005; Redelinghuys et al., 2006; Jullien et al., 2006; Corradi 
et al., 2007). 
The crystal structure of tACE in complex with RXPA380 revealed that the P2 Phe forms a 
favourable aromatic interaction with F391 (Corradi et al., 2007).  Initial docking experiments 
of the C-selective inhibitor keto-ACE, as well as its analogue kAW, into the C-domain active-
site indicated possible stacking interactions between the P2 Phe and F391 (Redelinghuys et al., 
2005; Tzakos and Gerothanassis, 2005; Redelinghuys et al., 2006).  These interactions would 
not only be lost  in the N-domain with the replacement of this residue with Y369, but steric 
hindrance, as is indicated by superimposition of the N-domain structure onto the tACE-
RXPA380 complex, would probably  result in a different orientation of the inhibitor within the 
active-site (Corradi et al., 2007).  Therefore, this aromatic interaction is believed to be a major 
factor in facilitating C-domain selectivity of the inhibitors RXPA380, keto-ACE and kAW. 
Furthermore, the positively charged P2 aspartate of RXP407 has been suggested to 
significantly contribute towards its N-selectivity (Dive et al., 1999; Jullien et al., 2006). 
Docked models of this inhibitor within the N-domain suggest hydrogen bond interactions 
between this group  and Y369 as well as R381, interactions that would not only be lost in the 
C-domain when replaced with Phe and Glu, respectively, but could possibly develop repulsive 
forces in the latter case (table 1.1) (Tzakos and Gerothanassis, 2005; Jullien et al., 2006; 
Corradi et al., 2006).
1.4.2.2 The S1 pocket
The three substitutions that occur within the S1 pocket of ACE are S516/N494, S517/V495 
and V518/T496 of tACE / N-domain, respectively (Bersanetti et al., 2004; Tzakos and 
Chapter 1: Review of the Literature
25
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Gerothanassis, 2005; Jullien et al., 2006).  The bulky P1 pseudo-Phe of keto-ACE is another 
moiety that has been implicated to contribute to the modest C-selectivity of this inhibitor 
(Acharya et al., 2003; Redelinghuys et al., 2005); however,  Tzakos et al. suggested that the 
40-fold preference of perindoprilat for the C-domain is probably partly due to favourable non-
polar interactions occurring between V518 and the P1 alkyl chain (Tzakos and Gerothanassis, 
2005).  Moreover, modelling of the C-domain-specific fluorogenic peptide, Abz-LFK(Dnp)-
OH into the tACE active-site indicated hydrophobic interactions between the P1 Leu and the 
V518 and S516 residues at distances of 2.3 and 5.0 Å, respectively  (Bersanetti et al., 2004). 
Replacement of this Val residue by T496 in the N-domain would decrease the hydrophobicity 
of this pocket, and therefore V518 is believed to play a significant role in the selectivity of 
these inhibitors and substrates.
1.4.2.3 The S1’ pocket
The tACE-lisinopril complex revealed a deep S1’ sub-site able to accommodate large, polar 
P1’ moieties (Natesh et al., 2003; Natesh et al., 2004).  The lysyl substituent of the modestly 
C-selective lisinopril has been shown to form hydrogen bond interactions with E162 and 
favourable water-mediated interactions with D377.  These electrostatic interactions are 
significantly lowered in the N-domain due to increased distances caused by replacement with 
D140 and Q355, respectively (Corradi et al., 2006).  
The marked C-domain selectivity of Abz-LFK(Dnp)-OH has been attributed to interaction of 
the P1’ Phe with these two S1’ residues, E162 and D377 (Bersanetti et al., 2004). 
Furthermore, Bersanetti et al. suggested that hydrophobic interaction of V380 , which they 
defined as an S1’ pocket residue, with this P1 Phe moiety facilitates favourable binding to the 
C-domain.
1.4.2.4 The S2’ pocket
This pocket is a large sub-site in both the N- and C-domains of ACE, able to tolerate a variety 
of inhibitor moieties.  The P2’ Trp of RXPA380 has been implicated to play a role in the C-
selectivity of this inhibitor (Georgiadis et al., 2004).  Interestingly, substitution of this position 
with a Trp or Phe side-chain in the ketomethylene derivatives kAW and kAF, respectively 
resulted in an increase in C-domain selectivity over that of keto-ACE (Redelinghuys et al., 
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2006).  A number of differences between domains have been identified within this sub-site, 
namely T282/S260, E376/D354, V379/S357, V380/T358 (V380 is defined as an S1’ pocket 
residue by some groups (Bersanetti et al., 2004; Tzakos and Gerothanassis, 2005)), and D453/
E431 in tACE / N-domain (table 1.1) (Georgiadis et al., 2004).
Most notable of these was the replacement of two hydrophobic Val residues with the N-
domain polar residues Ser and Thr, respectively.  The tACE-RXPA380 crystal structure 
revealed that the distance between the P2’ Trp and the C-domain valines is approximately 
4.5 Å, and the hydrophobicity of this pocket would entropically  exclude hydrophilic groups 
which would be more readily  accommodated in the N-domain S2’ pocket  (Georgiadis et al., 
2004; Corradi et al., 2007).  N-selectivity  of RXP407 seems to be attributed mainly  to the P2’ 
amidated C-terminus (Dive et  al., 1999), which suggests binding of this inhibitor in an 
extended conformation, allowing interaction of this side-chain with the acidic residues at  the 
opposite side of the pocket (Corradi et al., 2006).
Tzakos et al. suggested that the presence of the larger E431 and S260 side-chains in the N-
domain (replaced by Asp and Thr in the C-domain, respectively), may result in a reduction in 
the size of the N-domain pocket compared to that of the C-domain (tACE) (Tzakos and 
Gerothanassis, 2005).  Furthermore, the distance between the RXPA380 Trp and D453 was 
shown to be more than 5.5 Å, which precludes the formation of a hydrogen bond interaction 
(Georgiadis et al., 2004; Corradi et al., 2007).  Moreover, the favourable interactions between 
T282 and D453 and the dinitrophenyl group attached to the P2’ Phe of Abz-LFK(Dnp)-OH are 
also believed to contribute to the C-selectivity of this fluorogenic peptide (Bersanetti et al., 
2004).  It has therefore been suggested that a substituent extending toward the D453 residue, 
and exploiting this pocket more efficiently, may facilitate increased C-domain selectivity 
(Corradi et al., 2007).
Chapter 1: Review of the Literature
27
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Hypothesis
Particular residues within the active-site of the ACE protein confer C-domain specificity.
Aim and objectives of this study
A number of inhibitors able to discriminate between domains with a high degree of selectivity 
have been described to date, including the phosphinic peptide inhibitors RXPA380 and 
RXP407 (Dive et al., 1999; Georgiadis et  al., 2003), the keto-ACE derivatives kAW and kAF 
(Redelinghuys et  al., 2006), and the lisinopril-Trp derivative, lis-W (Nchinda et al., 2006a). 
Although similar, the N- and C-domains of ACE have demonstrated a number of differences 
with respect to their structure, and their substrate and inhibitor specificities.  The aim of this 
study was therefore to probe the contribution of particular residues within the different sub-
sites towards the domain specificity  of these inhibitors.  The information gained from this 
work should pave the way  to a better understanding of the active-site determinants of domain 
specificity.
The following objectives have been identified:
1. Construction of tACE mutants containing corresponding N-domain residues of 
 interest.
2. Expression and purification of mutant constructs.
3.  Kinetic characterisation of active constructs using domain-specific fluorogenic 
 peptides, and domain-selective inhibitors.
28
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Chapter 2:  Cloning and Mutagenesis of tACE 
Constructs
29
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
2.1 Introduction
To investigate the importance of particular active-site side-chains in ACE C-domain 
specificity, a series of tACE mutants were generated with selected amino acids converted to 
their N-domain counterparts by site-directed mutagenesis.  A number of residues were 
selected based on various observations of crystal structures and models of ACE in complex 
with different domain-specific ACE substrates and inhibitors, implicating particular residues 
in conferring this selectivity.
The objectives of the present work were therefore to:
1. To sub-clone the tACE"36NJ coding region, truncated between S625 and A626, and 
lacking the 36 N-terminal O-glycosylated region (making it identical to the C domain of 
sACE)(figure 2.1) (Yu et al., 1997), into the expression vector pcDNA3.1(+).
2. To engineer a stop codon downstream of tACE"36NJ, following the EcoRI site, to 
ensure proper termination of translation.
3. To sub-clone an appropriate fragment of the tACE coding region into the pGEM11Zf(+) 
shuttle vector to facilitate mutagenesis.
4. To generate a panel of mutants within the pGEM  - fragment shuttle construct  converting 
particular amino acids within the active-site to their corresponding N-domain residues.
5. To reintroduce these mutated fragments into the pcDNA-tACE"36NJ expression vector 
containing the stop codon, for transfection into mammalian cells.
Figure 2.1.  Schematic representation of the tACE!36NJ coding.  The region encoding the 
zinc-binding motif is highlighted in black.
ZBM
SphI EcoRIBamHI
5’ 3’
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2.2 Experimental procedure
2.2.1 Chemicals
Restriction endonucleases EcoRI, BglII, HindIII, NheI, SphI, BamHI, XhoI and restriction 
endonuclease buffers were acquired from Roche. JM109 cells, $ DNA, HpaI and restriction 
buffer, Pfu polymerase, polymerase buffer, polymerase chain reaction (PCR) nucleotide mix, 
MgCl2, DpnI, pGEM-11Zf(+) and the Wizard SV Gel System were all purchased from 
Promega.  Fermentas supplied NsbI (FspI), XmaJI, SspI and restriction buffers, while New 
England Biolabs supplied BsaAI and BbvCI with buffers.  T4 ligase and ligation buffer were 
obtained from USB, and pcDNA3.1(+) from Invitrogen.  The midi-prep plasmid purification 
kit was purchased from QIAGEN.  Inqaba Biotech, South Africa performed nucleotide 
sequencing and synthesised all primers.
2.2.2 Cloning
pSFV4.2-tACE"36NJ (obtained from E. D. Sturrock) and pcDNA3.1(+) were each digested 
with BamHI and EcoRI (described in Appendix I), and separated by agarose gel 
electrophoresis (Appendix I).  The bands of interest were excised from the gel, and purified 
using the Promega Wizard® SV Gel and Clean-Up System as per manufacturer’s instructions. 
The tACE"36NJ gene fragment and the digested  pcDNA3.1(+) vector were ligated (section 
2.2.2.1), and transformed into competent Escherichia coli (E. coli) JM109 cells (Appendix I). 
Ampicillin was used to facilitate selection of plasmid-containing colonies, and DNA was 
extracted (section 2.2.2.3).  Restriction endonucleases BglII and NheI were utilised to screen 
for the desired construct, pcDNA-tACE36NJ (figure 2.2), and fragments were visualised on 
agarose gels (Appendix I).  A stock solution of the plasmid construct was obtained using a 
QIAGEN midiprep kit in accordance with the manufacturer’s instructions (methods adapted 
from Ausubel et al., 1992).
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Figure 2.2.  Strategy used to sub-clone tACE!36NJ into the pcDNA3.1(+) expression 
vector, using restriction endonucleases BamHI and EcoRI.
2.2.2.1 Vector insert ligations
One µL of each digested, purified fragment was visualised on an agarose gel with DNA of 
known concentration to determine the insert and vector concentrations.  Ligation reaction 
mixtures (2 µL 10 x ligation buffer, 1 unit T4 ligase, appropriate DNA concentrations at a 
molar ratio of 3:1 vector to insert DNA, made up to 20 µL total volume with sterile de-ionised 
H2O (dH2O)) were incubated at room temperature overnight, and 10 µL was transformed into 
competent E. coli JM109 cells.  In the case of three part ligations, a DNA molar ratio of 3:1:1 
vector to insert to insert was used (method adapted from Ausubel et al., 1992).
2.2.2.2 Transformation of E. coli competent cells
Ten µL of ligation reaction mixture or PCR reaction mixture, was added to 200 µL of 
competent E. coli JM109 cells and incubated on ice for 1 hour.  DNA uptake was facilitated 
by heat shock at 42oC for 40 sec, followed by 2 min incubation on ice.  Nine hundred %L of 
LB medium was added to the cells, and the culture was shaken at 37oC for 1 hour to allow 
expression of the ampicillin gene.  Cells were centrifuged for 2 min, resuspended in 50 µL LB 
BamHI EcoRI
tACE"36NJ
Chapter 2: Cloning and Mutagenesis of tACE Constructs
32
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
broth, plated out on LB agar (15 g.L-1) plates containing 100 µg.mL-1 ampicillin and 
incubated at 37oC overnight (method adapted from Ausubel et al., 1992).
2.2.2.3 Mini-preparation plasmid DNA Isolation
This method was adapted from that in Sambrook and Russel (2001).  Transformed colonies 
were grown overnight shaking in 5 mL LB medium containing 100 µg.mL-1 ampicillin. 
One mL of the culture was harvested by  centrifugation for 2 min, and the pellet was 
resuspended in 250 µL STET buffer (233 mM  sucrose, 50 mg.mL-1 triton X-100, 50 mM 
ethylenediaminetetraacetic acid (EDTA), 50 mM Tris-HCl, pH 8.0), containing 1 mg.mL-1 
lysozyme.  Cells were boiled for 1 min and centrifuged for 8 min.  The pellet was removed 
using a toothpick, and 250 µL of isopropanol was added to the super atant, and centrifuged 
for 8 min.  The supernatant was discarded, and the pellet dried in a vacuum dryer, followed by 
resuspension in 20 µL 1/10 Tris-EDTA buffer (1 mM Tris-HCl, 0.1 mM  EDTA, pH 8.0).  To 
facilitate resuspension, DNA was heated at 60oC, and c ntrifuged for 2 min.  One-2 µL of 
mini-preparation DNA was used in restriction digests.
2.2.3 Sub-cloning of S2’ fragment into pGEM-11Zf(+)
A smaller fragment of tACE containing all of the residues of interest  was sub-cloned into 
pGEM-11Zf(+) (method adapted from Ausubel et al., 1992).  The restriction endonucleases 
utilised were EcoRI and SphI, producing a 1839 bp fragment containing all of the sites to be 
mutated.
An SphI site occurs more than once in the pcDNA3.1(+) vector, therefore pcDNA-
tACE"36NJ was first  digested with BamHI and EcoRI and the vector and insert were 
separated using agarose gel electrophoresis and purified (described above).  The insert was 
subsequently  digested with SphI, and pGEM-11Zf(+) with EcoRI and SphI.  Fragments were 
separated on agarose gels, excised and purified.  The SphI-EcoRI tACE fragment (which will 
be referred to as the S2’ fragment hereafter) and pGEM  vector were ligated and transformed 
into E. coli (described above).  Selection and screening was done as described above, using a 
double restriction endonuclease digest with NheI and HindIII, releasing a 515 bp band, to 
identify the pGEM-S2’ construct (figure 2.3).
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Figure 2.3.  Strategy used to sub-clone the tACE S2’ fragment into pGEM-Zf(+), using 
restriction endonucleases EcoRI and SphI.
2.2.4 Site-directed mutagenesis
A DpnI method, adapted from Papworth et al. (Papworth et al., 1996), was used to perform 
the site-directed mutagenesis.  It  involves the design of complementary primers, containing 
the desired mutation, which bind to a template plasmid containing the gene of interest.  A 
thermostable DNA polymerase with 3’ to 5’ exonuclease activity performs primer extension 
producing daughter strands consisting of the mutation of interest.  Design ensures that primers 
binding to daughter strands bind only to the 3’ end, and extension is therefore prohibited, 
preventing exponential amplification of any spurious mutations.  A number of temperature 
cycles of template separation, primer-template binding, and primer extension are performed, 
and template DNA is digested using DpnI endonuclease, selecting for the unmethylated, 
mutated DNA. This DNA can then be transformed into E. coli for DNA replication (figure 
2.4).
BamHI EcoRI
tACE"36NJ
SphI
BamHI + EcoRI
SphI
EcoRI
S2’ fragment
SphI
pcDNA-tACE"36NJ
(+)
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Figure 2.4.  Scheme representing the DpnI site-directed mutagenesis approach (taken 
from Papworth et al., 1996).
2.2.4.1 Stop codon insertion into pcDNA-tACE!36NJ
Due to the lack of a stop codon in the pcDNA-tACE"36NJ construct, this step was required 
to ensure proper termination of translation (new coding sequence see Appendix I).  The PCR 
amplification reaction mixture was prepared as follows:  5 µL 10 X polymerase buffer; 2 µL 
10 mM PCR nucleotide mix; 2 µL 10 µM forward primer (figure 2.5); 2 µL 10 µM reverse 
primer (figure 2.5); 5 µL 10 ng.µL-1 pcDNA-tACE"36NJ template; 4-8 µL 25 mM MgCl2; 2 
µL dimethyl sulphoxide (DMSO); 1.5 units Pfu polymerase; and sterile dH2O making the 
total volume up to 50 µL.  A control containing no template DNA was included, to ensure 
amplification was of the desired template.  The denaturation step was carried out at 94oC for 5 
min, followed by 16 cycles of 94oC for 30 sec, 55-56oC for 30 sec and 72oC for 12 min.  The 
mixture was then incubated at 72oC for 20 min, and stored at  4oC.  Amplification products 
were visualised on agarose gels.  2 µL of DpnI (20 units) was added to the reaction mixtures 
and incubated at 37oC for 1 hour.  Transformations into competent E. coli JM109 cells were 
performed using 10 µL of the digested reaction mixture.  DNA isolation (described above) 
was performed on colonies, which were screened with PstI and XmaJI restriction 
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endonucleases (figure 2.5), and visualised on agarose gels. Positive clones were then 
confirmed by nucleotide sequencing. 
Figure 2.5.  Primer design for insertion of a stop codon into pcDNA-tACE!36NJ. 
Complementary mutagenic primers (For, forward; Rev, reverse) were designed containing the 
mutation of interest, as well as a silent mutation introducing a unique restriction endonuclease 
site (RE) to facilitate screening.  Positive mutants were confirmed by nucleotide sequencing. 
The stop codon mutation appears in bold.  Silent mutations result in the insertion of an XmaJI 
site (underlined) and loss of a PstI restriction site to aid screening.
2.2.4.2 Conversion of S2’ tACE residues to corresponding N-domain residues
Reaction mixtures were set up  as for the stop  codon mutation above, replacing the pcDNA-
tACE"36NJ template DNA with pGEM-S2’, and the forward and reverse primers with those 
described in figure 2.6.  Appropriate temperature cycles were carried out, followed by  DpnI 
digestion on amplification products, transformation into competent E. coli JM109 cells, and 
DNA isolation of colonies (described above).  Restriction endonucleases used for screening 
are detailed in figure 2.6, and restriction digests were visualised on agarose gels.  Positive 
clones were confirmed by nucleotide sequencing.  Three part  ligations (section 2.2.2.1) were 
performed with the S2’ fragments containing the mutations of interest, along with the BamHI-
SphI fragment, and the pcDNA-tACE"36NJ vector DNA cut with BamHI and EcoRI (section 
2.2.3), to generate the pcDNA-tACE"36NJ constructs containing the desired mutation.
2.2.4.3  S2, S1 and S1’ pocket mutants
A number of tACE constructs containing N-domain substitutions within the S2 (F391Y, 
E403R), S1 (S516N, S517V, V518T) and S1’ (E162D, D377Q, ED/DQ) pockets (see table 2.1) 
were generated by a colleague (H. G. O’Neill) in a similar manner as described above.  Three 
multiple mutants were also created; TEVD (containing the mutations T282S, E376D, V380T 
and D453E), TEVVD (containing the V379S mutation in addition to the TEVD substitutions), 
and S2’F (which contains the F391Y mutation in addition to those in the TEVVD construct) 
(see table 2.1).  Except for E162D, all of the above mutations were generated using the 
Mutant Primer       RE
Stop  For 5’-CGCCGAATTCCTAGGATATCCAGCAC-3’ PstI
  Rev 5’-GTGCTGGATATCCTAGGAATTCGGCG-3’ XmaJI
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pGEM-S2’ shuttle vector described above.  The E162D substitution was performed using the 
pGEM-11Zf(-) vector, containing the BamHI-SphI fragment of the tACE&36NJ gene. 
Multiple mutants were obtained by sequential mutagenesis using previously mutated pGEM-
S2’ constructs as templates.
Figure 2.6.  Primer design for site-directed mutagenesis of S2’ mutants.  Complementary 
mutagenic primers (For, forward; Rev, reverse) are designed containing the mutation of 
interest, as well as a silent mutation introducing a unique restriction endonuclease site (RE) to 
facilitate screening.  Positive mutants were confirmed by nucleotide sequencing.  Residues in 
bold indicate the codon to be mutated, restrictions sites are underlined.  V380T also contained 
further silent mutations (grey, italics) to eliminate primer self-complementarity.  VV/ST 
contains both the V379S and V380T mutation.
2.3 Results and discussion
2.3.1 Sub-cloning
tACE"36NJ was inserted into the expression vector pcDNA3.1(+), and positive constructs 
were identified using restriction endonucleases.  A fragment encoding the S2’ residues of 
interest was sub-cloned from the pcDNA-tACE&36NJ construct into a pGEM11-Zf(+) 
Mutant Primer         RE
T282S   For 5’-GGGAACATGTGGGCGCAGAGTTGGTCCAATATTTATG-3’ 
  Rev 5’-CATAAATATTGGACCAACTCTGCGCCCACATGTTCCC-3’              SspI
E376D  For 5’-CACCGTTAACTTGGACGACCTGGTGGTGG-3’
  Rev 5’-CCACCACCAGGTCGTCCAAGTTAACGGTG-3’              HpaI
V379S  For 5’-GAACTTGGAGGACCTCAGCGTGGCCCACCACG-3’  
  Rev 5’-CGTGGTGGGCCACGCTGAGGTCCTCCAAGTTC-3’           BbvCI
V380T  For 5’-GGAGGACCTAGTAACTGCGCATCACGAAATGG-3’  
  Rev 5’-CCATTTCGTGATGCGCAGTTAGTAGG CCTCC-3’              NsbI
VV/ST  For 5’-GAACTTGGAGGACCTCAGCACAGCCCACCACGAAATGG-3’
  Rev 5’-CCATTTCGTGGTGGGCTGTGCTGAGGTCCTCCAAGTTC-3’         BbvCI
D453E  For 5’-GATGAAGATGGCCCTCGAGAAGATCGCCTTTATCC-3’  
  Rev 5’-GGATAAAGGCGATCTTCTCGAGGGCCATCTTCATC-3’              XhoI
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cloning vector for subsequent site-directed mutagenesis.  The smaller S2’ fragment was 
utilised to facilitate nucleotide sequencing and reduce the occurrence of spurious mutations.
Positive pGEM-S2’ clones displayed the presence of two bands (3182 and 1137 bp)  when cut 
with EcoRI and SphI (figure 2.7, lane 2), compared to the empty pGEM11-Zf(+) vector that 
displays only one visible band of 3182 bp (figure 2.7, lane 1).  Furthermore, co-digestion with 
NheI and HindIII revealed the presence of two bands 3804 and 515 bp in size (figure 2.7, lane 
4), compared to the empty vector displaying one band of 3221 bp (figure 2.7, lane 3).
Figure 2.7.  Sub-cloning of S2’ fragment into pGEM-11Zf(+).  Colonies were screened with 
restriction endonucleases as follows:  pGEM-11Zf(+) cut with EcoRI and SphI (lane 1); 
pGEM-S2’ cut with EcoRI and SphI (lane 2); pGEM-11Zf(+) cut with NheI and HindIII (lane 
3); pGEM-S2’ cut with NheI and HindIII (lane 4).  Lambda DNA digested with EcoRI and 
HindIII was used as a molecular marker (lane MM).
2.3.2 Site-directed mutagenesis
2.3.2.1 Stop codon insertion into pcDNA-tACE!36NJ
Because there was no stop  codon in the pcDNA-tACE"36NJ construct, one was inserted 
downstream of the EcoRI restriction site to ensure proper termination of translation.  The 
mutagenic primer (figure 2.5) removed and introduced the restriction endonuclease sites PstI 
and XmaJI, respectively.  Positive clones displayed the disappearance of the two 1356 and 
1156 bp bands (figure 2.8, lane 2), and the appearance of a 2512 band (figure 2.8, lane 3) for 
PstI digestion, while XmaJI digestion resulted in the appearance of two 1097 and 6170 bp 
bands (figure 2.8, lane 4), compared to the unmutated construct, which is linearised (figure 
2.8, lane 5).  Sequences were confirmed by nucleotide sequencing.
MM
21 226 -
5148 -
2027 -
947 -
564 -
1     2     3     4
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Figure 2.8.  Stop codon was inserted into the pcDNAtACE!36NJ construct downstream 
of the tACE gene.  Colonies were screened with restriction endonucleases as follows:  uncut 
pcDNAtACE (lane 1); pcDNAtACE cut with PstI (lane 2) and XmaJI (lane 5); and 
pcDNAtACE with the stop codon mutation cut with PstI (lane 3) and XmaJI (lane 4). 
Lambda DNA digested with EcoRI and HindIII was used as a molecular marker (lane MM) 
for each gel.
2.3.2.2 Construction of active-site mutants
The selection of mutants generated (table 2.1) was based on a number of studies that have 
identified differences between domains, within the sub-site pockets of ACE (discussed in 
section 1.3) (Natesh et al., 2003; Georgiadis et al., 2004; Bersanetti et  al., 2004; Redelinghuys 
et al., 2005; Tzakos and Gerothanassis, 2005; Redelinghuys et al., 2006; Jullien et al., 2006; 
Corradi et al., 2006; Corradi et al., 2007).  
Site-directed mutagenesis was performed in the pGEM-S2’ shuttle construct.  S2’ residues 
were converted to their corresponding N-domain residues.  In the first attempt, PCR products 
were obtained for mutants V379S, VV379/380ST and D453E,  transformed into E. coli, and 
screened with the appropriate restriction endonucleases.  
MM    1       2      3 MM        4        5
21 226 -
   5148 -
   2027 -
     947 -
     564 -
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Table 2.1.  Summary of the mutants generated.
Pocket Mutant Name tACE (C-domain) N-domain
S2 F391Y Phe 391 (967) Tyr 369
E403R Glu 404 (979) Arg 381
S1 S516N Ser 516 (1092) Asn 494
S517V Ser 517 (1093) Val 495
V518T Val 518 (1094) Thr 496
S1’ E162D Glu 162 (738) Asp 140
D377Q Asp 377 (953) Gln 355
ED/DQ Glu 162, Asp 377 Asp 140, Gln 355
S2’ T282S Thr 282 (858) Ser 260
E376D Glu 376 (952) Asp 354
V379S Val 379 (955) Ser 357
V380T Val 380 (956) Thr 358
VV/ST Val 379, Val 380 Ser 357, Thr 358
D453E Asp 453 Glu 431
S2’ multiple TEVVD T282, E376, V379, 
V380, D453
S260, D354, S357,  
T358, E431
TEVD T282, E376, V380, D453 S260, D354,  T358, E431
S2’ and S2 multiple S2’F T282, E376, V379, 
V380, D453, F391
S260, D354, S357,  
T358, E431, Y369
The pGEM-S2’ plasmid encodes a 1139 bp fragment of the coding sequence of tACE between 
the restriction endonuclease sites EcoRI and SphI (described in 2.2.3).  The uncut plasmid 
resolved as two bands representing supercoiled and nicked plasmid DNA (figure 2.9, lanes 1, 
3 and 5).  The pGEM-S2’ V379S, VV/ST and D453E plasmids encode the same sequence 
except containing Val 379 to Ser, Val 379 and Val 380 to Ser and Thr, and Asp 453 to Glu 
substitutions, respectively (table 2.1).  The identity of positive clones were confirmed by 
restriction endonuclease analysis (figure 2.9).  The pGEM-S2’ V379S, VV/ST and D453E 
plasmids were linearised by digestion with BbvCI, BbvCI and XhoI, respectively, yielding 
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single bands (4319 bp) in agreement with the expected size.  Sequences were confirmed by 
nucleotide sequencing.
Figure 2.9.  The S2’ residues of interest were converted from C-domain to corresponding 
N-domain residues by site-directed mutagenesis, using a DpnI PCR method.  Mutants 
were screened with appropriate restriction endonucleases as follows:  A, pGEM-S2’ (lane 1) 
and pGEM-S2’ V379S (lane 2) digested with BbvCI; B, pGEM-S2’ (lane 3) and pGEM-S2’ 
VV379/380ST (lane 4) digested with BbvCI; and C, pGEM-S2’ (lane 5) and pGEM-S2’ 
D453E (lane 6) digested with XhoI.  All clones were confirmed by nucleotide sequencing. 
Lambda DNA digested with EcoRI and HindIII was used as a molecular marker (lane MM) 
for each gel.
A Mg concentration titration (representative gel, figure 2.10) was performed to obtain 
products for the T282S, E376D and V380T mutants.  Pfu polymerase requires free Mg to 
function, however Mg also binds to the nucleotides and DNA, decreasing the specificity of 
the primer for the template (Innis and Gelfand, 1990).  Therefore an increased Mg 
concentration often improves the product yield for a primer with a number of mismatches. 
This increased concentration can, however, also cause the production of non-specific 
products; hence the process sometimes requires some optimisation (Henegariu et al., 1997). 
Further optimisation of these PCR reactions also involved the addition of DMSO.  This is 
believed to improve the efficiency of the amplification in a number of ways including 
affecting primer melting temperature (Tm) and / or the polymerase activity profile and 
increasing the product yield (Innis and Gelfand, 1990).
A MM     1        2 B MM      3        4 C MM      5        6
21 226 -
5148 -
2027 -
  947 -
  564 -
V379S VV/ST D453E
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Figure 2.10.  Representative gel of a Mg titration in a PCR reaction.  Final Mg 
concentrations 0, 2, 4, 6 and 8 mM (lanes 1-5, respectively), molecular marker (lane MM).
A final concentration of 6 mM Mg yielded appropriate PCR products for each of the above 
constructs.  The E376D mutagenic primer introduced a unique HpaI restriction endonuclease 
site.  The unmutated pGEM-S2’ plasmid ran as uncut plasmid DNA with two bands 
(supercoiled and nicked plasmid DNA; figure 2.11 A, lane 1), and a putative mutant plasmid 
was identified with the linearisation of the pGEM-S2’ E376D construct, revealing a single 
band of 4319 bp (figure 2.11 A, lanes 1 and 2).  No putative mutant plasmids were identified 
from the T282S and V380T products.
Figure 2.11.  The S2’ residues of interest were converted from C-domain to corresponding 
N-domain residues by site-directed mutagenesis, using a DpnI PCR method.  Mutants 
were screened with appropriate restriction enzymes as follows:  A, pGEM-S2’ (lane 1) and 
pGEM-S2’ E376D (lane 2) digested with HpaI; B, pGEM-S2’ (lane 2) and pGEM-S2’ T282S 
(lane 3) digested with SspI; and C, pGEM-S2’ (lane 4) and pGEM-S2’ V380T (lane 5) digested 
with NsbI.  All mutations were confirmed by nucleotide sequencing.  Lambda DNA digested 
with EcoRI and HindIII was used as a molecular marker (lane MM) for each gel.
The original T282S primer was 45 bp  in length (Appendix I, figure A1).  This length was used 
because a single silent mutation only produced a BmrI restriction endonuclease site 22 bp 
1   2    3   4   5
21 226 -
5148 -
2027 -
947 -
564 -
MM
A B CMM     1        2 MM      3        4 MM      5        6
21 226 -
   5148 -
   2027 -
     947 -
     564 -
E376D T282S V380T
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away from the mutated codon.  When the primer was re-analysed, it was found that if two 
silent mutations were used, an SspI restriction site could be engineered 12 bp  from the 
mutated codon, allowing the design of a primer 37 bp in length.  This primer (figure 2.6) 
introduced a third SspI restriction endonuclease site, cutting a 3883-bp fragment into two 
2214 and 1669 bp  fragments. Template pGEM-S2’ DNA ran as two bands, 3883 and 436 bp, 
while a putative mutant plasmid was identified, displaying the presence of three bands 2214, 
1669 and 436 bp in size  (figure 2.11 B, lanes 3 and 4).
The original primer designed for V380T contained the V/T mutation 6 bp from the end of the 
oligonucleotides (Appendix I, figure A1).  This primer was however unsuccessful in 
producing a mutant plasmid, possibly  due to the primer not annealing to the desired site, and 
redesign of the primer involved the inclusion of an additional two silent mutations to 
eliminate self-complementarity (figure 2.6).  The new V380T mutagenic primer introduced a 
third NsbI restriction site, causing a 2842-bp band to be cut into two 1909 and 933 bp bands. 
Unmutated pGEM-S2’ plasmid revealed two bands (2842 and 1477 bp), and a potential 
mutant plasmid was identified by the presence of three bands of 1909, 1477 and 933 bp 
(figure 2.11 C, lanes 5 and 6).
As mentioned above, the S2, S1, S1’ and multiple mutants were generated by a colleague (H.G. 
O’Neill) using a similar approach to that used to construct the S2’ mutants.  All constructs 
were confirmed by nucleotide sequencing.
The tACE S2’ fragments containing the corresponding N-domain mutations of interest were 
cut out of the pGEM-S2’ constructs using EcoRI and SphI, and reintroduced into the pcDNA-
tACE"36NJ vector construct by a three part ligation with the S2’ fragments containing the 
mutations of interest, the BamHI-SphI fragment, and the pcDNA-tACE"36NJ vector DNA 
cut with BamHI and EcoRI (described in section 2.2.2.1).  All plasmid constructs were 
confirmed using cloning and unique site restriction endonuclease sites introduced in the site-
directed mutagenesis.
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2.4 Summary
In summary, the tACE"36NJ gene was sub-cloned into the pcDNA3.1(+) expression vector, 
and a fragment containing the residues to be mutated (S2’ fragment) was sub-cloned into the 
shuttle vector pGEM11Zf(+) to facilitate site-directed mutagenesis.  Residues of interest were 
converted to their corresponding N-domain counterparts using a DpnI mutagenesis method, 
and positive clones were identified using restriction endonucleases, and confirmed by 
nucleotide sequencing.  The mutated S2’ fragments were re-introduced back into the pcDNA-
tACE"36NJ construct by a three part ligation, for subsequent expression in mammalian cells.
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3.1 Introduction 
A panel of tACE mutants was generated (described in chapter 2; see table 2.1) containing 
particular active-site residue N-domain substitutions.  These were transfected into CHO cells 
not expressing endogenous ACE, and mutant protein was expressed and purified for 
subsequent enzyme kinetic analysis.  Constructs were characterised using the domain-
selective FRET peptides Abz-LFK(Dnp)-OH (C-domain-selective) and Abz-SDK(Dnp)P-OH 
(N-domain-selective).
The objectives of the present work were therefore to:
1. Transfect  the plasmids encoding soluble tACE mutants into CHO cells and harvest 
media containing these protein constructs.
2. Confirm activity of mutant constructs using an HHL activity assay.
3. Isolate tACE mutant constructs using a Sepharose-28-lisinopril affinity  column, and N-
domain using immuno-affinity chromatography.
4. Determine the active concentration of each construct using an active-site titration.
5. Characterise the hydrolysis of domain-specific fluorogenic peptides by particular 
mutant constructs.
3.2 Experimental procedure
3.2.1 Chemicals
Fetal calf serum (FCS) and trypsin were supplied by Gibco, and Dulbecco’s modified eagle’s 
medium (DMEM) and Ham’s F12 were obtained from Highveld Biologicals.  N-2-
hydroxyethylpiperazine-N’-2-ethanesulphonic Acid (HEPES), G418, HHL, HL, Z-FHL, o-
phthaldialdehyde, protein G agarose and ZnCl2 were purchased from Sigma.  Chinese hamster 
ovary K1 (CHO-K1) cells were supplied by American Type Culture Collection (ATCC® 
CCL-61), the Profection! Mammalian Transfection System from Promega, and the BIO 
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RAD protein assay from BIO RAD.  Ethanolamine was from Saarchem, NaCl from Merck, 
and lisinopril from Zeneca Pharmaceuticals.
3.2.2 Expression of constructs
pcDNAtACE"36NJ mutant constructs were transfected into CHO-K1 cells using the 
Profection! Mammalian Transfection System.  Ten mL of CHO-K1 growth medium 
(50 % DMEM, 50 % Ham’s F12, 20 mM  HEPES, pH 7.5, supplemented with 10 % FCS 
(heat-inactivated for 30 min at 56oC)) was inoculated with 500 µL of a CHO-K1 stock 
solution, and incubated at 37oC, 5 % CO2, until confluent.  Cells were seeded into 10 cm2 
culture dishes and incubated overnight, as before.  Three hours before transfection, the cells 
were washed with 1 x phosphate-buffered saline (PBS) and further incubated with fresh 
growth medium.  A 500 µL solution containing 10 µg of DNA and 248 mM CaCl2 was 
bubbled through 500 µL of HEPES buffered saline, incubated at room temperature for 
30 min, and added drop-wise to the cells.  Cells were incubated for 3-4 hours, glycerol-
shocked at room temperature for 1.5-2 min using 15 % glycerol in PBS, and then washed with 
PBS.  Cells were then incubated in CHO-K1 growth medium overnight at 37oC, 5 % CO2. 
The following day, medium was replaced with 0.8 mg.mL-1 G418-supplemented medium to 
select for positive colonies, and incubated until separate clones of approximately 1-2 mm 
were visible.  Colonies were picked using sterile swabs dipped in trypsin-EDTA, and seeded 
into 12 well plates.  Clonal lines were screened for ACE activity (section 3.2.3), and stocks 
were prepared from the clone exhibiting the highest ACE activity  using HHL for tACE and 
tACE constructs, and Z-FHL for the N-domain. 
3.2.3 HHL and Z-FHL assays
ACE cleaves the substrates HHL and Z-FHL to produce the product HL.  The latter forms a 
fluorescent adduct with o-phthaldialdehyde, which can be measured spectrofluorometrically 
($ excitation = 360 nm; $ emission = 485 nm) (Friedland and Silverstein, 1976).  Medium or 
purified samples (2-20 µL) were incubated with 120 µL HHL substrate in HHL assay buffer 
(5.7 mM  HHL in 50 mM HEPES, pH 7.5, 0.3 M  NaCl; Appendix II), or 120 µL Z-FHL in Z-
FHL buffer (1 mM Z-FHL in 0.1 M  KPO4 buffer, pH 8.3, 0.3 M NaCl, 10 µM ZnSO4; 
Appendix II) at 37oC for 15 min, and the reaction was stopped with 725 µL 0.028 M  NaOH. 
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Fifty µL of 20 mg.mL-1 o-phthaldialdehyde was added, incubated at room temperature for 
10 min, and the reaction stopped with 100 µL 3 M  hydrochloric acid.  Fluorescence was 
measured from 250 %L of the reaction mixture in a 96 well plate, using a Varian Eclipse 
Fluorescence Spectrophotometer.  An HL standard curve (0-20 nmol HL) was generated to 
convert fluorescent units into milliunits (mU) ACE activity, where 1 unit is defined as 1 
nmole of HL produced per min-1.mL-1, at 37oC in HHL assay buffer.
3.2.4 Isolation and purification of tACE modified derivatives
CHO-K1 clonal lines were grown up  in growth medium, and transferred to T175 cm2 flasks. 
Once 90 - 100 % confluent, medium was replaced with growth medium (50 % DMEM, 50 % 
Ham’s F12, 20 mM HEPES, supplemented with 2 % FCS (heat-inactivated for a further 15 
min at 70oC), and media were harvested every 2 - 3 days.  Harvested media were stored at 
-20oC until required for purification.
Testis ACE proteins were purified from spent growth media with affinity  chromatography, 
using a Sepharose-28-lisinopril affinity column (Ehlers et al., 1991).  Ten mL Columns were 
washed with wash buffer (20 mM HEPES, pH 7.5, 0.5 M NaCl)  to eliminate non-specific 
binding and the tACE and mutant derivatives were eluted with 50 mM borate buffer (pH 9.5), 
of which 1.5 mL fractions were collected and analysed for ACE activity.  Those containing 
substantial ACE activity were pooled and dialysed overnight in 2 x 2 L of dialysis solution (5 
mM HEPES, pH 7.5) 0.1 mM PMSF) at 4oC.  Protein concentrations were determined using a 
BIORAD Bradford assay as per manufacturer’s instruction, and activity was measured using 
the HHL assay.  Purified proteins were visualised on a 10 % polyacrylamide sodium 
dodecylsulphate gel electrophoresis (SDS-PAGE) gel (Laemmli, 1970) to ensure purity  and 
correct size.  Purified protein aliquots of 0.5 - 1 mL were stored at 4 and -20oC.
3.2.5 Isolation and purification of N-domain derivatives of sACE
A CHO-K1 cell line expressing a soluble N-domain derivative D629, containing the N-
terminal residues 1-629 of sACE (a kind gift from S. M. Danilov; Balyasnikova et al., 2003), 
sub-cloned (by P. Redelinghuys) into the expression vector pcDNA3.1(+) using the restriction 
endonucleases XbaI and EcoRI, was obtained from S. L. W. Schwager, and harvested medium 
was prepared and stored as described above.
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Protein G is an immunoglobulin-binding protein able to bind the Fc segment of mammalian 
IgG (Sjöbring et al., 1990).  It is therefore commonly used to remove excess levels of this 
protein from culture medium.  To improve selectivity  of the N-domain immuno-affinity 
chromatography  column, spent medium was passed through a pre-protein G agarose column 
to reduce the excess levels of IgG, and N-domain was consequently bound to an N-domain-
specific antibody, 5C5 (kindly provided by S. M. Danilov), coupled to a protein G agarose 
column (Corradi et al., 2006).  The columns were washed with wash buffer as described 
above, and elution of the N-domain was mediated with 50 mM ethanolamine (pH 11.5). 
Protein was collected, dialysed, analysed and stored as described above.
3.2.6 Fluorogenic peptide assay
Domain-selective internally quenched FRET peptides, containing an Abz fluorescent donor 
and a Dnp acceptor group, were used to characterise the activity  of ACE.  Cleavage of these 
peptides between the donor-acceptor pair releases fluorescence that can be measured 
continuously in a fluorometer (Yaron et al., 1979; Araujo et al., 1999).  
The fluorogenic peptides (kind gifts from A. K. Carmona), supplied in powder form, were 
dissolved in a small volume of DMSO to approximately 10 mM.  Concentrations (C) were 
calculated based on the Beer-Lambert equation A = E.C.l, where the extinction coefficient (E) 
was 17300 M-1cm-1, absorbance (A) of the stock solutions was measured at 365 nm, and the 
pathlength (l) of the cell was 1 cm.  Stock solutions of 1 mM  were made up in DMSO, and 
working solutions were made up from these stocks in the FRET assay buffer constituting 
50 mM HEPES buffer (pH 6.8), 200 mM NaCl, and 10 %M ZnCl2.
Cleavage of these peptides was characterised in a continuous assay at ambient temperature 
(20 - 25oC), under initial rate conditions of less than 10 % hydrolysis, over time (s).  Briefly, 
in triplicate, 0.2 nM enzyme was added to substrate concentration ranges of 0 - 12 %M, to 
final volumes of 300 %L in the FRET assay buffer (adjusted from Carmona et al., 2006), and 
fluorescence was measured at $ex = 320 nm and $em = 420 nm.  A standard curve converting 
fluorescence to nmol product was generated from total hydrolysis of fluorogenic peptides 
(Appendix II).  Kinetic parameters were calculated using the Direct Linear plot method 
(Eisenthal and Cornish-Bowden, 1974), and all replicates displayed an error within 5 %.
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3.2.7 Active enzyme concentration determination
In order to determine more accurate concentrations of active enzyme present, active-site 
titrations were performed with the inhibitor lisinopril, known to bind in a ratio of 1:1, 
inhibitor molecule to enzyme active-site.  Limitations of this method include the high 
concentrations of enzyme and inhibitor that should ideally be used to ensure that  the 
E + I ⇌ EI reaction is driven mainly to the right (Bieth, 1995).  Stock solutions of lisinopril 
were made by dissolving the inhibitor in dH2O and preparing a dilution series in the FRET 
assay buffer.  Active-site titrations were performed by  incubating 10 %L enzyme (in the assay 
buffer) with an equal volume of each of the lisinopril dilutions for 1.5 hours at ambient 
temperature.  Residual enzyme activity  was measured, by pipetting out 20 %L of the 
incubation mixture into a 96-well plate, adding Abz-FRK(Dnp)P-OH (4 %M final substrate 
concentration), to a total volume of 300 %L, in triplicate, and measuring the continuous 
fluorescence at $ex = 320 nm and $em = 420 nm, at ambient temperature.
The active-site concentration was calculated as described by Knight, 1995 (Knight, 1995). 
Briefly, the stoichiometry of inhibition (SI) value was calculated from a plot of percent 
activity versus the molar ratio of lisinopril to ACE (I:E; protein concentrations of ACE were 
determined from Bradford’s assays).  The x-intercept of the initial portion indicates the SI, 
where the ratio of the number of moles of inhibitor is equal to that of the enzyme in the case 
of ACE and lisinopril (SI = 1).  Based on this expectation, we can determine the active protein 
concentration by  multiplying the total protein concentration determined by the Bradford’s 
assay, by the SI value calculated from the plot.
3.3 Results and discussion
3.3.1 Protein expression and purification
CHO cell lines expressing adequate levels of tACE, N-domain and tACE active-site mutants 
were established by transfection, and the line exhibiting the highest HHL activity was selected 
for protein expression. Pooled media containing expressed protein were applied to a 
Sepharose-28-lisinopril affinity  column for purification of tACE constructs, and N-domain 
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was purified using an immuno-affinity  column.  Each protein construct was analysed on an 
SDS-PAGE gel to confirm size and purity.  Bands for all the mutants were observed to have a 
molecular weight of approximately  78 kDa, which was in good agreement with the calculated 
weight of 78 kDa for fully glycosylated tACE"36NJ (representative SDS-PAGE in 
figure 3.1).  This molecular weight was calculated using the tACE"36NJ sequence and 
adding six glycans of 1700 Da each.  
Figure 3.1.  Representative SDS-PAGE (10 %) indicating purity of a selection of tACE 
mutants.  Lanes 1, tACE; 2, VV/ST; 3, D453E; 4, T282S; 5,V379S; 6, V380T; 7, E376D. 
Lanes were loaded with approximately  10 µg of protein.  Arrow indicates the size of the tACE 
constructs (78 kDa). Molecular marker (lane MM) sizes in kDa. 
Bradford assays were performed to determine protein concentration and calculate yields of 
purified protein (table 3.1; Bradford, 1976) with total protein obtained ranging from 0.2 to 6 
mg, and HHL assays were performed to confirm ACE activity in all constructs.  Interestingly, 
high yields were obtained for most of the mutants, particularly  for E376D and D453E.  These 
are believed to be extremely high expressing cell lines, as similar yields were obtained in 
subsequent transfections and purifications.  This phenomenon could be due to either multiple 
insertion of the gene into the genome or perhaps the active-site substitution plays some role in 
improving the stablility of the final protein product.
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Table 3.1.  Summary of protein purification yields from CHO-K1 cells.
Protein
derivative
Protein Yield
(mg.L-1 medium)
Protein
derivative
Protein Yield
(mg.L-1 medium)
tACE 2.1 T282S 4.4
N-domain 7.4 E376D 25.7
F391Y 2.3 V379S 3.4
E403R 1.1 V380T 1.2
S516N 3.8 VV/ST 7.2
S517V 1.8 D453E 12.3
V518T 1.1 S2’ 7.3
E162D 2.6 TEVD 11.3
D377Q 1.7 S2’F 3.2
ED/DQ 3.1
3.3.2 Active enzyme concentration determination
Although affinity chromatography is assumed to result in a fully  active stock solution of the 
enzyme, degradation of protein may occur when stored for long periods of time, resulting in 
lowered concentrations of active enzyme (Knight, 1995).  Furthermore, inaccurate 
measurements can be obtained from absorbance readings due to dissolved contaminants or 
tightly bound water molecules.  Active concentrations of each construct were therefore 
determined using active-site titrations with the tight-binding inhibitor lisinopril, before 
performing any subsequent fluorogenic assays (representative active site titration, figure 3.2).
Generally, the active-site concentrations obtained using this method were approximately 
10-25 % of those displayed by the Bradford’s method (results not shown).  These assays were 
however performed on samples that had been stored for more than a month at  4oC, in 5 mM 
HEPES and no NaCl.  It was also found that under these conditions, certain mutants, 
particularly V518T, demonstrated rapid degradation within a week (figure 3.3).  Furthermore, 
there are a number of limitations to the Bradford’s method, such as its sensitivity  to protein 
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composition and non-protein contaminants (Bradford, 1976).  This highlights the importance 
of accurately determining the active concentration of a construct before subsequent kinetic 
analysis, to ensure that the effect of amino acid substitutions can be correctly  attributed to 
their effects on binding and catalysis, as opposed to their influence on protein stability 
(Knight, 1995).
Figure 3.2.  Plot of percentage activity versus the molar ratio of inhibitor to enzyme.  The 
SI value is indicated.
Optimisation of storage conditions for the V518T mutant was carried out by storing stocks at 
different HEPES and NaCl concentrations.  Three stock samples of V518T were stored in 
5 mM  HEPES (no NaCl), 25 mM  HEPES 100 mM  NaCl and 50 mM HEPES 200 mM NaCl, 
(all pH 7.5) at 4oC, for one month.  Complete and slight degradation of the 5 mM  and 50 mM 
HEPES sample was observed, respectively, while the 25 mM HEPES sample displayed none 
(figure 3.3A).  Furthermore, storage of S516N in 5 mM  HEPES at -20oC resulted in less 
degradation of protein than those stored at 4oC (figure 3.3B).  It can be therefore be suggested 
that ACE constructs containing active site mutations, should ideally be stored at -20oC in 
5 mM HEPES, or in 25 mM HEPES.
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Figure 3.3.  SDS-PAGE (10 %, denaturing) displaying A) V518T and B) S516N  mutants 
stored under different conditions for one month.  Lane 1, 5 mM  HEPES, no NaCl (4oC); 2, 
50 mM HEPES, 200 mM NaCl (4oC); 3, 25 mM HEPES, 100 mM NaCl (4oC); 4, 5 mM 
HEPES (-20oC); 5, 5 mM HEPES (4oC).  Lanes were loaded with approximately  10 µg of 
protein.  Lane MM, molecular marker, sizes in kDa.
3.3.3 Hydrolysis of FRET peptides
Kinetic constants were calculated for the hydrolysis of FRET peptides Abz-LFK(Dnp)-OH 
and Abz-SDK(Dnp)P-OH, by tACE, N-domain and the tACE mutants (tables 3.2 and 3.3).
3.3.3.1 Hydrolysis of Abz-LFK(Dnp)-OH
Abz-LFK(Dnp)-OH, which is cleaved by ACE at the Leu-Phe bond, is highly selective for the 
C-domain (Bersanetti et al., 2004).  This selectivity has mainly been attributed to the high 
catalytic rate with which this substrate is cleaved by the C-domain compared to the N-
domain.  This effect was observed here too (table 3.2), where the kcat value for tACE (53.3 s-1) 
was 120-fold greater than that of the N-domain (0.44 s-1), while the KM values were similar 
(tACE, 14.5 %M; N-domain, 9.5 %M).
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Table 3.2.  Kinetic constants for the cleavage of the C-domain-specific Abz-LFK(Dnp)-
OH FRET peptide by ACE constructs.  Cleavage of Abz-LFK(Dnp)-OH by a series of 
tACE mutants and the wild-type tACE and N-domain constructs was analysed.  Initial 
velocities for each substrate concentration were determined in triplicate, and kinetic constants 
were calculated using the direct linear plot method (Eisenthal and Cornish-Bowden, 1974).
Mutant
Abz-LFK(Dnp)-OH
                   KM("M)                                           kcat (s-1)
tACE 14.5 53.3
Ndom 9.5 0.44
S516N 12.5 30.2
V518T 16.7 27.6
E162D 13.9 50.0
D377Q 7.5 18.0
ED/DQ 8.8 25.6
V379S 3.5 23.4
V380T 5.3 18.2
VV/ST 2.4 18.2
To elucidate the molecular basis for this selectivity, the hydrolysis of Abz-LFK(Dnp)-OH by a 
selection of tACE active-site mutants was tested (table 3.2).  These mutants were chosen 
based on pockets implicated to play  a role in the C-selectivity  of Abz-LFK(Dnp)-OH through 
scanning of peptide libraries with differing P3 to P1’ substituents (particularly S1’) (Bersanetti 
et al., 2004), as well as analysis of specific interactions of a docked model of Abz-LFK(Dnp)-
OH complexed to tACE (particular residues within the S1 and S2’ pocket) (Bersanetti et al., 
2004).  As expected, there was not much variation with the KM values, with the lowest KM 
values being obtained for mutations within the S2’ pocket, V379S, V380T and VV/ST (3.5, 
5.3 and 2.4, respectively; table 3.2; figure 3.4).  
Slight decreases in kcat, approximately 3-fold, were observed for D377Q, V380T and VV/ST 
(kcat = 18.0, 18.2, 18.2 s-1, respectively).  The substitution of a Gln residue for the Asp in 
D377Q not only results in the loss of a negative charge, but could potentially  position the 
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polar Gln side-chain closer to the P1’ Phe side-chain of Abz-LFK(Dnp)-OH than the shorter 
Asp (5.8 Å for Q, compared to 7.5 Å for D; figure 3.4).  The mutations V380T and VV/ST 
decrease the hydrophobicity of the S2’ pocket.  A model of Abz-LFK(Dnp)-OH docked into 
the active-site of tACE (figure 3.4) (Bersanetti et al., 2004) revealed distances of 
approximately 7.8 and 3.8 Å between the P2’ Phe and residues V379 and V380, respectively. 
Therefore, the VV/ST substitution’s effect is likely due to the V380T mutation, as is further 
evidenced by  a similar kcat obtained for this single mutation, compared to the double mutant 
(table 3.2).  All of these substitutions are more than 10 Å away from any of the residues 
believed to play a role in stabilising the transition state and are therefore unlikely to play  a 
direct role in hindering the formation of the tetrahedral intermediate.  It can be suggested 
however, that these conversions may cause a change in the orientation of the substrate 
molecule, which may  result in unfavourable interactions with these stabilising residues, 
thereby reducing the efficiency with which the substrate is cleaved.
None of these mutations caused a decrease in kcat equivalent to that of the N-domain, 
suggesting that other residues within the active-site contribute to the high selectivity  of this 
substrate for the C-domain (discussed below).  Furthermore, additional factors such as access 
of the substrate into the active-site and interactions of the substrate with residues elsewhere in 
the protein, such as the lid region or entrance to the active-site, may also contribute to some 
extent.  This idea is supported by a tACE construct  developed in our group, containing an N-
domain-like lid region, where tACE residues 1-163 were replaced by the corresponding N-
domain residues 1-141 (Woodman et al., 2006).  This construct revealed interesting shifts in 
substrate specificity displaying catalytic efficiencies more comparable to that of the N-
domain, for the C-selective substrates HHL and Abz-LFK(Dnp)-OH.  This implies that the lid 
region of the N-domain may play a role in access or release of the substrate or products, 
affecting the efficiency with which particular substrates are cleaved.
Another example of factors outside the active-site affecting substrate specificity  was 
demonstrated by Behera and Mazumdar (Behera and Mazumdar, 2008).  They showed that 
Cytochrome P450cam, an oxygenase from Pseudomonas putida involved in camphor 
metabolism, contains residues at  the entrance to the putative substrate access channel that 
seem to play a major role in the binding and recognition of camphor, therefore facilitating 
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access of this substrate into the active-site.  This suggests that other proteins such as ACE, 
may have residues at the entrance to or in the substrate channel that may contribute to 
substrate specificity, especially considering the lid regions of these two domains display  a low 
sequence identity (approximately 25 %), with some interesting differences in charge and 
hydrophobicity (Woodman et al., 2006).
Figure 3.4.  Stick representation of Abz-LFK(Dnp)-OH (grey carbon atoms) docked into 
the tACE active-site (PDB code 1o86) (kindly  provided by  A.T. Nchinda; Bersanetti et al., 
2004), aligned to the N-domain structure (PDB code 2c6n).  Residues differing between tACE 
and the N-domain are shown in yellow and purple, respectively, tACE residues stabilising the 
transition state are coloured green. The active-site zinc ion is represented as a grey sphere and 
two of the zinc-chelating residues are shown as black lines (H383 and H387).  All distances 
are given in Å.  Images were created using MacPyMOL 0.99 (DeLano Scientific, Palo Alto, 
CA, U.S.A).
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Further analysis of residues within 6 Å of Abz-LFK(Dnp)-OH in the docked tACE structure 
(Bersanetti et al., 2004) aligned to the N-domain (PDB code 2c6n), revealed some interesting 
differences between the two active-sites (figure 3.5).  In addition to the residues that were 
mutated above (table 3.2), N277 (Asp  255 in the N-domain) and S461 (Gly 439 in the N-
domain) differed between domains.  Moreover, a residue conserved between domains, D465/
D443 (tACE / N-domain numbering), was within 6 Å of the substrate side-chain for the N-
domain, while the distance in tACE was greater than 6 Å (figure 3.5).
Figure 3.5.  Additional residues that may play a role in the C-domain-specificity of Abz-
LFK(Dnp)-OH (docked model kindly  provided by A.T. Nchinda; Bersanetti et al., 2004), 
aligned to the N-domain structure (PDB code 2c6n).  Residues differing between tACE and 
the N-domain are shown in yellow and purple, respectively. The active-site zinc ion is 
represented as a grey  sphere and two of the zinc-chelating residues are shown as black lines 
(His 383 and His 387).  All distances are given in Å.  
N277 is a polar hydrophilic amino acid, which probably does not  interact favourably  with the 
substrate P1’ Phe (figure 3.5).  The N-domain substitution of an Asp in this position would 
introduce an acidic, negatively charged amino acid, making the interaction between these 
residues even less favourable.  Replacement of the tACE S461 residue with the N-domain Gly 
N277/D255
S461/G439
D465/D443
4.55
6.73
5.52
5.53
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would decrease the size and hydrophilicity of this residue interacting with the hydrophilic 
Dnp group (figure 3.5).  D443 (N-domain) and D445 (tACE) are approximately  4.6 and 6.7 Å 
from the  oxygens of the Dnp moiety, respectively  (figure 3.5).  This difference could result  in 
a notably altered orientation of the substrate, which could ultimately  lead to a much lowered 
catalytic efficiency.  Support for these ideas would however, require further mutational and 
kinetic studies, involving converting the tACE or N-domain residues to the corresponding 
domain counterparts, or for the cases of conserved residues, converting them to amino acids 
of similar size, but different properties.
3.3.3.2 Hydrolysis of Abz-SDK(Dnp)P-OH
The KM values obtained for the cleavage of Abz-SDK(Dnp)P-OH by tACE and the N-domain 
were 7.3 and 7.7, respectively (table 3.3).  These results, although slightly lower, are 
consistent with those reported by Araujo et al. (Araujo et al., 2000).  A 4.5-fold selectivity 
was observed for the catalytic activity  of the N-domain over that of tACE (tACE , kcat = 0.31 
s-1; N-domain, kcat = 1.4 s-1; table 3.3).  Araujo et al. (Araujo et al., 2000) found that N-
selectivity is increased for fluorogenic peptides with a Ser and Asp in the P2 and P1 positions, 
respectively, while residues differing in the P1’ and P2’  positions had minimal effect on N-
specificity.  This led us to test  the hydrolysis of Abz-SDK(Dnp)P-OH with the S2 and S1 
pocket mutants described above (table 3.3).  Again, the KM values were similar for all the 
proteins tested (table 3.3), however no increase in kcat from that of tACE was observed (table 
3.3).  Therefore the modest 4.5-fold selectivity of Abz-SDK(Dnp)P-OH for the N-domain 
may be due to other factors such as access of the peptide to the active-site and/or interactions 
of the peptide elsewhere in the active-site or in the remainder of the protein (discussed above).
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Table 3.3.  Kinetic constants for the cleavage of the N-domain-specific Abz-SDK(Dnp)P-
OH FRET peptide by ACE constructs.  Cleavage of Abz-SDK(Dnp)P-OH by a series of 
tACE mutants and the wild-type tACE and N-domain constructs was analysed.  Initial 
velocities for each substrate concentration were determined in triplicate, and kinetic constants 
were calculated using the direct linear plot method (Eisenthal and Cornish-Bowden, 1974).
Mutant
Abz-SDK(Dnp)P-OH
                    KM("M)                                         kcat (s-1)
tACE 7.3 0.31
Ndom 7.7 1.4
E403R 4.1 0.18
F391Y 10.9 0.22
S516N 15.2 0.17
S517V 11.5 0.14
V518T 9.7 0.57
The 4-fold N-selectivity  of Abz-SDK(Dnp)P-OH determined in this study was dramatically 
lower than the 250-fold selectivity  reported by Araujo et al. (Araujo et al., 2000).  A number 
of factors can explain this discrepancy.  Firstly, there were some differences in the method 
employed for the reaction, such as the temperature at which the reactions were performed 
(37oC by Araujo et al. compared to 25oC in this work), and the use of cuvettes with final 
volumes of 2 mL (Araujo et al.) versus white 96 well plates using final volumes of 300 %L. 
However, repeating these assays using similar techniques to those employed by Araujo et al. 
(Araujo et al., 2000) yielded similar results to those obtained in table 3.3 (results not shown). 
Secondly, the mutant proteins used in each study were different; Araujo et al. used full-length 
proteins with an inactivated domain, while we used soluble single domains (described in 2.1 
and 3.2.5).  Furthermore, work demonstrating the N-specificity  of the naturally occurring 
ACE substrate, AcSDKP, was also performed on full-length ACE mutants containing one of 
the two catalytic sites inactivated  (Rousseau et al., 1995).  This suggests that the marked 
selectivity observed by Araujo et al. (Araujo et al., 2000) and Rousseau et al. (Rousseau et al., 
1995) for Abz-SDK(Dnp)P-OH and AcSDKP, respectively, may be partly due to interactions 
between the two domains of ACE as evidenced by a high degree of co-operativity previously 
observed between the domains  (Ehlers and Riordan, 1991; Binevski et al., 2003; Woodman et 
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al., 2005; Skirgello et al., 2005; Andújar-Sánchez et al., 2007;), rather than specific residues 
within the active-site that seem to contribute only slightly (table 3.3).  
Araujo et al. (Araujo et al., 2000) reported that Abz-SDK(Dnp)P-OH, containing Abz and 
Dnp moieties, was hydrolysed more efficiently than the naturally occurring N-domain-
specific substrate, AcSDKP (Rousseau et al., 1995; Araujo et al., 2000).  This result was not 
confirmed in this work, since the catalytic efficacy of ACE for Abz-SDK(Dnp)P-OH was 
markedly lower than that reported by Araujo et al. (Araujo et al., 2000).  Structure-function 
studies were also performed by Michaud et al. (Michaud et al., 1999), substituting the N-
terminal acetyl-Ser with a BzGly.  This substrate demonstrated a 5-fold lower N-selectivity 
(kcat / KM) compared to that of AcSDKP, however, this change was mainly attributed to an 
increased KM and only  slightly increased kcat.  Further work is being performed by another 
member of our group (R. G. Douglas) to investigate these phenomena. 
3.4 Summary
In summary, all of the active-site mutant proteins were successfully expressed and isolated. 
Particular tACE active-site mutants were analysed with the FRET peptides Abz-LFK(Dnp)-
OH (C-domain-selective) and Abz-SDK(Dnp)P-OH (N-domain-selective).  Comparable KM 
values were obtained amongst the different peptides for those tACE constructs tested, while 
some variation was observed with the kcat results.  However, for the two domain-selective 
substrates, no shift in kcat was equivalent to that of the N-domain from tACE.  Therefore the 
selectivity of these substrates is probably a result of a combination of factors, such as active-
site residues as well as interactions elsewhere in the protein.
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4.1 Introduction
Although the C- and N-domains of ACE display almost 60 % sequence identity, they have 
demonstrated a number of interesting differences, particularly  in their substrate and inhibitor 
specificities.  Over the past decade, a number of highly domain-selective ACE inhibitors have 
been described.  These include two phosphinic peptide inhibitors, RXP407 and RXPA380 
(Dive et al., 1999; Georgiadis et  al., 2003), two keto-ACE derivatives, kAW and kAF 
(Redelinghuys et al., 2006), and the lisinopril analogue lis-W (Nchinda et al., 2006a) (figure 
1.8).  
Dive et al. have described two phosphinic inhibitors, RXP407 and RXPA380, each 
demonstrating a selectivity of three orders of magnitude for the N- and C-domains, 
respectively (Dive et  al., 1999; Georgiadis et al., 2003).  The selectivity of RXP407 has been 
attributed to three structural features of this compound: the presence of a carboxyamide group 
on the P2’ Ala, an aspartic acid moiety  in the P2 position, and the presence of an acetyl group 
on this N-terminal Asp (Dive et al., 1999).  Structure-function studies of RXPA380 analogues 
revealed that the P2’ Trp played an important role in the marked C-selectivity of this inhibitor 
(Georgiadis et al., 2004).  More recently, crystallographic data has provided evidence that the 
hydrophobic interaction of the P2 Phe with the S2 F391 residue could also play a critical role 
in the domain specificity  of RXPA380 (Corradi et al., 2007).  These two phosphinic peptide 
inhibitors were therefore used to probe the importance of the S2 and S2’ sub-sites in ACE 
domain selectivity.
Keto-ACE is an analogue of the tripeptide ACE substrate, Bz-Phe-Gly-Pro (Weare et al., 
1981), which binds the catalytic zinc ion of ACE via its ketone group.  It  displays inhibition in 
the nanomolar range, with a modest 30- to 40-fold C-domain selectivity believed to reside in 
its bulky P1 moiety and the benzyl substituent in the P2 position (Acharya et al., 2003; 
Deddish et al., 1998).  Using keto-ACE as a platform, our group has synthesised a number of 
novel derivatives containing modified P1’ and P2’ substituents (Nchinda et al., 2006b).  Two of 
these compounds, kAW and kAF, containing P2’ Trp and Phe substituents, respectively, have 
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demonstrated some interesting C-selectivity (Redelinghuys et  al., 2006).  These three 
inhibitors are all similar in structure differing only  at  their P2’ substituent, and therefore 
providing some interesting tools to investigate particular interactions between the P2’ 
substituent and S2’ residues such as V379 (tACE numbering).  Furthermore, although it  has a 
ketone zinc binding group, versus the phosphinic group of RXPA380, kAW has similar P2, P1 
and P2’ substituents to those of RXPA380.  Therefore, comparison of results between these 
two inhibitors could provide important insights into the effects of the different zinc co-
ordinating moieties versus the sub-site pocket side-chains.
Lisinopril is a potent ACE inhibitor widely used for the treatment of hypertension and CVD. 
This compound was also used by  our group as a platform to develop more domain-selective 
inhibitors of ACE.  Substitution of the P2’ group  with a Trp moiety  results in two enantiomers, 
S- and R-lis-W (figure 4.1).  Previous work reported the S-isomer displaying more potent 
inhibition of tACE compared to that of the R-isomer (Nchinda et al., 2006a).  Moreover, 
attempts to crystallise R-lis-W complexed with tACE resulted in ACE co-crystals containing 
the S-enantiomer within the active-site (Watermeyer, 2008).  This suggests that the C-domain 
active-site selected for the S-isomer, which could have been present in trace amounts in the 
purified R-lis-W solution.  Watermeyer suggested that occlusion of the R-enantiomer is 
probably  caused by steric hindrance between the alcohol group of Y523 and the # carbon of 
the P1 Phe  (Watermeyer, 2008).  This selection is consistent with previous reports of ACE 
inhibitors containing an S-configuration in this position displaying markedly higher affinities 
over their R-counterparts (Brenner et al., 1990; Stefan et al., 1998).  Furthermore, this 
configuration is consistent with the L-amino acid chirality observed in biological peptides.
The aim of this work was to gain a better understanding of the molecular basis to ACE 
domain selectivity.  This panel of inhibitors provides an excellent tool to characterise 
important interactions by analysing the effect  of binding to tACE active-site mutants 
containing relevant N-domain substitutions.  The results of these studies provide useful 
insight into specific residues driving the domain selectivity of ACE.
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Figure 4.1.  The S- and R-enantiomers of lis-W.  The star indicates the chiral centre 
concerned, and R1 represents the remainder of lis-W (the P1’ and P2’ substituents).
The objectives of the present work were therefore to:
1. Characterise the hydrolysis of the non-domain-specific fluorogenic peptide Abz-
FRK(Dnp)P-OH by mutant constructs.
2. Perform kinetic characterisation of the panel of domain-selective inhibitors, using tACE 
mutant proteins containing active-site substitutions potentially forming interactions 
conferring selectivity.
4.2 Experimental procedures
4.2.1 Chemicals
Acetonitrile (ACN) was purchased from Burdick and Jackson, and trifluoroacetic acid (TFA) 
was supplied by Merck.
4.2.2 Preparation of Abz-FRK(Dnp)P-OH
Fluorogenic peptides were prepared as described in section 3.2.6.
4.2.3 Preparation of inhibitors
The phosphinic peptide inhibitors RXP407 and RXPA380 were kindly provided by  V. Dive 
(Dive et al., 1999; Georgiadis et al., 2003).  Keto-ACE and its derivatives kAW and kAF were 
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synthesised by  A. T. Nchinda (Nchinda et al., 2006b).  Lis-W was synthesised by  A. Mahajan 
(Nchinda et  al., 2006a) and the S- and R-isomers were separated by S. L. W. Schwager using 
high-performance liquid chromatography (HPLC) (section 4.2.4).
Phosphinic peptide inhibitors, lisinopril and lis-W were dissolved in dH2O, while keto-ACE 
and its derivatives were dissolved in a small volume of DMSO.  An appropriate dilution series 
was prepared for each inhibitor in FRET assay buffer (section 3.2.6).   
4.2.4 Purification of lis-W isomers
The separation of the lis-W enantiomers was achieved by HPLC, using a semi-preparative 
reversed-phase column (TRACER EXCEL TR-016174 120ODSB, 5 %m, 25 cm x 1 cm; from 
Teknokroma), with a gradient elution 26-30 % ACN in 0.1 % TFA over 30 min, at a flow rate 
of 2.5 mL.min-1.  Peaks were detected at the UV wavelengths 215 and 280 nm.  The R-isomer 
eluted at tR = 27 min, while the S counterpart eluted at tR = 33 min.  The structure and purity 
of the S-isomer of lis-W was confirmed by nuclear magnetic resonance, as this was the only 
isomer found to co-crystalise with tACE (Watermeyer, 2008), and has been shown to be C-
domain-selective (Nchinda et al., 2006a).
4.2.4 Fluorogenic assay
The fluorogenic assay was performed using the non-domain-selective peptide Abz-
FRK(Dnp)P-OH, as described in section 3.2.6.
4.2.5 Inhibition assay
Approximately  0.2 nM of enzyme was incubated with an appropriate concentration range of 
inhibitor, at ambient temperature (20 - 25oC) for 60 min.  For inhibitors dissolved in DMSO, 
the final concentration of this solvent was below 1 %.  Twenty %L of this enzyme-inhibitor 
mixture, was added, in triplicate, to a reaction mixture of 4 or 8 %M  Abz-FRK(Dnp)P-OH in 
FRET assay buffer, to a final volume of 300 %L.  Residual enzyme activity was monitored by 
fluorescence, as described in section 3.2.6.  
Inhibition constants were calculated using the Dixon method (Dixon, 1953).  Briefly, linear 
regression curves were plotted on a graph of the reciprocal of initial velocities (v, defined 
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as < 10 % of substrate hydrolysis) versus inhibitor concentrations, using GraphPad Prism 
4.01.  The point of intersection, m1! + c1 =  m2! + c2, corresponds to the negative Ki value, 
where m = gradient, ! = x co-ordinate and c = y-intercept (figure 4.2).
Figure 4.2.  Representative Dixon plot.  N-domain inhibition by  lisinopril at two substrate 
concentrations: 4 (squares) and 8 (triangles) %M Abz-FRK(Dnp)P-OH.
4.3 Results and discussion
Mutant proteins having key  residues replaced with their N-domain counterparts (see table 
2.1), were characterised using a series of domain-selective inhibitors, with the fluorogenic 
substrate Abz-FRK(Dnp)P-OH.
4.3.1 Hydrolysis of Abz-FRK(Dnp)P-OH
Abz-FRK(Dnp)P-OH has been shown to display  little selectivity between the ACE domains 
(Araujo et al., 2000) and was therefore used for characterising the interaction of mutants with 
the domain-selective inhibitors.  The C- (tACE) and N-domain constructs demonstrated KM 
values of 3.9 and 3.7 %M, respectively, for the hydrolysis of Abz-FRK(Dnp)P-OH, consistent 
with those reported by Araujo et al. (Araujo et al., 2000).  All of the mutants displayed similar 
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KM values but there was greater variation amongst the kcat values, ranging from 0.6 to 37 s-1 
for the E376D mutant and TEVVD, respectively (table 4.1).
Table 4.1.  Summary of kinetic constants for the cleavage of the Abz-FRK(Dnp)P-OH 
FRET peptide by ACE constructs.  Cleavage of Abz-FRK(Dnp)P-OH by a series of tACE 
mutants as well as the wild-type tACE and N-domain proteins was analysed.  Initial velocities 
for each substrate concentration were determined in triplicate, and kinetic constants were 
calculated using the direct linear plot method (Eisenthal and Cornish-Bowden, 1974).
Mutant
Abz-FRK(Dnp)P-OH
                     KM("M)                                            kcat (s-1)
tACE 3.9 25.6
Ndom 3.7 11.4
E403R 3.7 30.2
F391Y 10.3 4.5
S516N 10.6 3.9
V518T 12.0 6.9
E162D 4.5 22.5
D377Q 4.0 9.2
ED/DQ 6.5 16.5
T282S 5.0 1.2
E376D 9.9 0.6
V379S 5.9 29.6
V380T 10.6 27.0
VV/ST 6.8 33.0
D453E 5.5 5.5
TEVD 26.8 27.7
TEVVD 18.4 36.8
S2’F 6.7 28.8
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4.3.2 Domain selectivity of the phosphinic inhibitors
RXPA380 displayed C-domain-specific inhibition of the hydrolysis of Abz-FRK(Dnp)P-OH, 
with an approximately 880-fold higher affinity for the C-domain than for the N-domain (table 
4.2, figure 4.3).  In contrast, RXP407 demonstrated potent inhibition of the N-domain, with a 
more than 500-fold selectivity over that of the C-domain (table 4.2).  Both of these trends are 
consistent with previously published data (Dive et al., 1999; Georgiadis et al., 2003).  The 
inhibition of the active-site mutants will be discussed in detail under the various sub-sites later 
in this chapter.
Table 4.2.  Kinetic parameters for the inhibition of ACE activity by RXPA380 and 
RXP407.  Inhibition constants for wild-type tACE and N-domain, as well as tACE active-site 
mutants containing corresponding N-domain residue substitutions, using the fluorogenic 
peptide Abz-FRK(Dnp)P-OH, were determined using the Dixon method (Dixon, 1953).
Construct Pocket RXPA380
Ki (nM)
RXP407
Ki (nM)
tACE (C-domain) - 69 2800
N-domain - 60900 5.2
F391Y S2 2326 1500
E403R S2 97.5 1800
V518T S1 276 11000
T282S S2’ 251 n.d.
E376D S2’ 363 n.d.
V379S S2’ 36.4 330
V380T S2’ 462 800
VV/ST S2’ 177 1100
D453E S2’ 288 n.d.
TEVD S2’ 2236 6600
TEVVD S2’ 1160 760
S2’F S2’ and S2 5300 16.1
n.d. not determined.
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Figure 4.3.  Log scale comparison of the relative binding affinities of tACE active-site 
mutants for RXPA380 with that of wild-type tACE (C-domain).  Values above zero 
represent a decrease in affinity relative to that of tACE, towards a more N-domain-like Ki.  
4.3.3 Domain selectivity of keto-ACE and its derivatives
Under the conditions described, keto-ACE displayed a 30-fold higher affinity  for the C-
domain (Ki = 0.05 %M) than for the N-domain (Ki = 1.5 %M, table 4.3).   Two novel C-
domain-selective keto-ACE derivatives have been developed in our group, kAW and kAF, 
containing a Trp  and Phe residue in the P2’ position, respectively.  Due to solubility problems 
with kAF, a Ki value for the N-domain was not obtainable, however no inhibition was 
observed up  to 500 %M (table 4.3).  These inhibitors both demonstrated high domain 
selectivity under the conditions tested (table 4.3), with kAW and kAF having approximately 
1200- and >600-fold higher affinity for the C-domain, respectively (figure 4.4).  However, it 
should be noted that the potency of these inhibitors for the C-domain is approximately 10-fold 
lower than that obtained for RXPA380 and keto-ACE.  The inhibition of the active-site 
mutants will be discussed in detail under the various sub-sites later in this chapter.
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Table 4.3.  Kinetic parameters for the inhibition of ACE activity by keto-ACE, kAW and 
kAF.  Inhibition constants for wild-type tACE and N-domain, as well as tACE active-site 
mutants containing corresponding N-domain residue substitutions, using the fluorogenic 
peptide Abz-FRK(Dnp)P-OH, were determined using the Dixon method (Dixon, 1953).
Construct Pocket keto-ACE
Ki ("M)
kAW
Ki ("M)
kAF
Ki ("M)
tACE (C-domain) - 0.05 0.68 0.83
N-domain - 1.5 854 >500
F391Y S2 0.43 4.8 3.9
E403R S2 n.d. 0.24 n.d.
S516N S1 0.012 0.50 n.d.
V518T S1 1.3 9.7 18.1
T282S S2’ n.d. 0.92 n.d.
E376D S2’ n.d. 2.3 2.4
V379S S2’ n.d. 0.064 0.81
V380T S2’ n.d. 2.7 1.9
VV/ST S2’ n.d. 0.87 n.d.
D453E S2’ n.d. 0.62 n.d.
n.d. not determined.
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Figure 4.4.  Log scale comparison of the relative binding affinities of tACE active-site 
mutants for kAW (black bars) and kAF (grey bars), with that of wild-type tACE (C-
domain) (adapted from Watermeyer et al., 2008).  Values above zero represent a decrease 
in affinity  relative to that of tACE, towards a more N-domain-like Ki.  Ki’s were not 
determined for T282S, VV/ST, D453E, S516N and E403R with kAF as these mutations did 
not cause a noticeable shift for keto-ACE or kAW (table 4.2).
4.3.4 Domain selectivity of lisinopril and lis-W
Lisinopril is a potent ACE inhibitor, demonstrating modest domain selectivity  (tACE Ki = 1.2 
nM, N-domain Ki = 4.8 nM; table 4.4).  Inhibition by  the S-enantiomer of lis-W displayed Ki’s 
of 6.6 nM  and 1700 nM  for tACE and N-domain, respectively (table 4.4, figure 4.5).  The 
inhibition of the active-site mutants will be discussed in detail under the various sub-sites later 
in this chapter.
Resolution of the tACE–lis-W (S-enantiomer) crystal structure revealed lis-W is bound in a 
very similar conformation to lisinopril within the active-site of tACE, but with a slight 
deviation in the position of the P1’ lysyl amine (Watermeyer, 2008) (see figure 4.9). 
Interestingly, the P2’ Trp moiety is in a different orientation than that observed in the 
RXPA380 and kAW structures.  This difference has been attributed to strong entropically 
favourable hydrophobic interactions between the P1’ Lys and the tACE V380 residue. 
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Moreover, this new orientation allows the formation of a hydrogen bond interaction between 
the indole N and D415, a residue that is conserved between domains.  In the kAW structure, 
this N is shown to form hydrogen bond interactions with water molecules within this pocket 
(Watermeyer et al., 2008; Watermeyer, 2008).
Table 4.4.  Kinetic parameters for the inhibition of ACE by lisinopril and lis-W. 
Inhibition constants for wild-type tACE and N-domain, as well as tACE active-site mutants 
containing corresponding N-domain residue substitutions, using the fluorogenic peptide Abz-
FRK(Dnp)P-OH, were determined using the Dixon method (Dixon, 1953).
Construct Pocket lisinopril
Ki (nM)
lis-W
Ki (nM)
tACE (C-domain) - 1.2 6.6
N-domain - 4.8 1700
F391Y S2 n.d. 9.7
V518T S1 1.6 8.7
E162D S1’ 0.83 8.5
D377Q S1’ 1.3 17.5
ED/DQ S1’ 0.89 26.5
T282S S2’ n.d. 10.3
E376D S2’ n.d. 24.8
V379S S2’ n.d. 2.1
V380T S2’ 0.3 1.1
VV/ST S2’ 0.7 9.5
D453E S2’ n.d. 15.6
TEVD S2’ n.d. 75.4
TEVVD S2’ n.d. 104.6
n.d. not determined.
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Figure 4.5.  Comparison of the relative binding affinities of tACE active-site mutants for 
lisinopril (black bars) and lis-W (grey bars) with that of wild-type tACE (C-domain). 
Values above zero represent a decrease in affinity relative to that of tACE, towards a more N-
domain-like Ki.  Ki’s were not determined for F391Y, T282S, E376D, V379S, D453E, TEVD 
and TEVVD with lisinopril, as these residues were not expected to play a role in lisinopril 
binding.
4.3.5 Roles of tACE active-site residues in the selectivity of C-domain-selective inhibitors
In order to gain a better understanding of the roles of the various active-site residues in 
inhibitor binding, we tested these selective inhibitors against the mutants generated.
4.3.5.1 Roles of S2 residues
The highest shift in Ki observed for the single mutations when tested with RXPA380 was a 
34-fold increase from that of tACE (Ki = 69 nM) for F391Y (Ki = 2326 nM; table 4.2, figure 
4.3).  This mutant protein also demonstrated a considerable decrease in affinity for keto-ACE 
and its derivatives, relative to that of tACE (table 4.3, figure 4.3).  The E403R mutant 
displayed no change in affinity  for the inhibitors tested, kAW or RXPA380, compared to that 
of wild-type tACE (tables 4.2 and 4.3, figures 4.3 and 4.4). 
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The tACE-RXPA380 crystal structure (PDB code 2oc2) revealed a hydrophobic interaction 
between the inhibitor P2 Phe and F391 of tACE in the S2 pocket (Corradi et al., 2007).  This 
interaction seems to be responsible for positioning the inhibitor optimally within the active-
site, and would be lost in the N-domain where this residue is replaced by  Y369 (figure 4.6A). 
Moreover, the hydroxyl group of this Tyr may result in steric hindrance with the inhibitor Phe, 
which could result in RXPA380 adopting a different orientation within the N-domain active-
site (figure 4.7).  Therefore, based on the X-ray  crystal structure and mutational and kinetic 
analysis, it is likely that F391 makes a critical contribution to the C-domain specificity of 
RXPA380.
The structures of tACE in complex with kAW (PDB code 3bkl) and kAF (3bkk) revealed 
hydrophobic contacts between the inhibitor P2 group and F391 (figure 4.6B and C, 
respectively) (Watermeyer et al., 2008).  The hydroxyl group introduced into this pocket by 
the N-domain Y369 would result in steric hindrance with the binding of keto-ACE (or its 
derivatives) containing a benzoyl moiety in this position, reducing the affinity with which 
these inhibitors would bind.
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Figure 4.6.  Stick representation of inhibitors A) RXPA380 (PDB code 2oc2) (Corradi et 
al., 2007), B) kAW (3bkl) (Watermeyer et al., 2008) and C) kAF (3bkk) (Watermeyer et 
al., 2008) within the tACE active-site, aligned with the N-domain (2c6n).  Particular 
residues differing between tACE and the N-domain are shown in yellow and purple sticks, 
respectively.  The active-site zinc ion is represented by a grey  sphere, and two of the two zinc-
chelating residues (H383 and H387) are shown in black lines.  All distances are given in Å. 
Images were created using MacPyMOL 0.99 (DeLano Scientific, Palo Alto, CA, U.S.A).
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Figure 4.7.  Sphere representation of RXPA380 (yellow carbons) and N-domain Y369 
(purple carbons).  Red and blue spheres represent oxygen and nitrogen, respectively. 
Surface representation of the N-domain represented in green.  This model was obtained by 
aligning the N-domain-lisinopril structure (PDB code 2c6n) with the tACE-RXPA380 co-
crystal structure.  It is clear from this diagram that there may  be steric clash within this pocket 
(S2), which would probably  result in the inhibitor adopting a different orientation within the 
N-domain.
4.3.5.2 Roles of S1 residues
For keto-ACE, the V518T mutation (Ki = 1.3 %M) caused a marked decrease (26-fold) in 
affinity, resulting in a Ki equivalent to that of the N-domain (Ki = 1.5 %M; table 4.3).  Notable 
decreases in affinity were also observed for kAW and kAF (table 4.3, figure 4.4), while a 
slight decrease (4-fold) and no change in affinity  were displayed for RXPA380 (table 4.2, 
figure 4.3) and lis-W (table 4.4, figure 4.5), respectively.  The S516N mutant displayed no 
change in affinity  for kAW and the phosphinic inhibitor RXPA380, while a slight increase in 
affinity was observed with keto-ACE (tables 4.2 and 4.3, figures 4.4 and 4.5).
Substitution of Val with a Thr in the V518T mutant protein is unlikely to cause any  steric 
hindrance within this pocket; however, the N-domain T496 would decrease the 
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hydrophobicity of this pocket, which could result in less favourable binding of keto-ACE and 
its derivatives (figures 4.6B, 4.6C and 4.8) (Watermeyer et al., 2008).
Figure 4.8.  Sphere representation of kAW (green) and N-domain T496 (yellow).  The N-
domain-lisinopril structure (PDB code 2c6n) was aligned to the tACE-kAW co-crystal 
structure (3bkl).  It is clear from this diagram that there may  be unfavourable interactions 
within this pocket (S1) due to the increased hydrophilicity  caused by the Val to Thr 
substitution (V518T).  This could result in the inhibitor binding with a markedly lower 
affinity, as evidenced by the change in Ki’s (table 4.3).
4.3.5.3 Roles of S1’ residues in lisinopril and lis-W binding
Interestingly, the S1’ mutations E162D, D377Q and the double mutant ED/DQ (see table 2.1) 
had no effect on the minor C-selectivity  of lisinopril (table 4.4, figure 4.5).  The E162D 
construct also showed no difference for the highly  C-selective lis-W, however the D377Q and 
ED/DQ mutations caused slight increases in Ki’s (2.7- and 4-fold, respectively; table 4.4, 
figure 4.5).  
Although the resolution of the N-domain-lisinopril structure is limited, it does imply a slightly 
different backbone confirmation for the P1’ lysyl side-chain compared to that within the tACE 
T496
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complex (Natesh et al., 2003; Corradi et  al., 2006).  It has been suggested that the mild C-
domain selectivity demonstrated by this inhibitor could be attributed to the electrostatic 
interaction between the lysyl amine and D162, which is assumed to be lost in the N-domain 
where the distance between these two groups is 6.5 Å (Corradi et al., 2006).  However, no 
shift in affinity was observed with the E162D mutant (table 4.4, figure 4.9).  This observation 
could be explained in two ways.  Firstly, scaffolding residues surrounding E162 in tACE (and 
Asp in the E162D mutant) may  hold this residue in a conformation or position that facilitates 
ideal electrostatic interaction with the inhibitor, while residues supporting D140 in the N-
domain do not enable such interactions.  Secondly, this N-domain Asp  residue (in E162D) is 
still located on the tACE backbone which does display small differences in conformation in 
this region when aligned to the N-domain backbone.  Therefore the proximity  of this Asp in 
tACE E162D to the lysyl amine in this protein may  still be close enough for the occurrence of 
favourable electrostatic interactions.  Hence, E162 may contribute towards lisinopril’s C-
selectivity, however crystallographic data of E162D would provide conclusive evidence in 
this regard.  A similar result was obtained for lis-W, however the selectivity of this inhibitor is 
probably more reliant on the P2’ Trp (discussed below).
Figure 4.9.  Stick representation of lisinopril (green, PDB code 1o86) and lis-W (orange)
(Watermeyer, 2008) within the active-site of tACE, aligned with the N-domain (2c6n). 
Residues differing between tACE and the N-domain are shown in yellow and purple sticks, 
respectively.  The active-site zinc ion is represented by a grey sphere, and two of the three 
zinc-chelating residues (H383 and H387) are shown in black lines.  Distances between the 
inhibitor S1’ amide and V380T are given in Å.
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D377 in tACE has been shown to establish favourable water-mediated interactions with 
lisinopril’s P1’ lysine (figure 4.9) (Natesh et al., 2003; Corradi et  al., 2006).  The presence of 
these water molecules in the N-domain-lisinopril structure was not apparent owing to the 
lower resolution of the structure obtained (Corradi et al., 2006), therefore it is not clear 
whether this residue plays a role in the slight C-selectivity of lisinopril, but because of the 
lack of any  shift in Ki for this mutant (D377Q; table 4.4) it is likely  that it plays a negligible 
role.  The minor shift observed for this mutant with lis-W from that of tACE (table 4.4), may 
be due to the effect of the P2’ Trp.  The presence of this hydrophobic moiety  may  occlude 
water molecules needed for this interaction, thereby decreasing the binding affinity to this 
mutant (figure 4.9).
4.3.5.4 Roles of S2’ residues in binding of inhibitors containing a P2’ Trp or Phe
For most of the single S2’ mutants (and double mutant VV/ST), only slight decreases in 
affinity were observed, if any.  The highest shifts in affinity  for RXPA380 and the keto-ACE 
derivative inhibitors within this pocket were displayed by  V380T and E376D (tables 4.2 and 
4.3, figures 4.3 and 4.4).  Lis-W also displayed a decrease in Ki for the E376D mutant, 
however a slight increase in affinity was observed for V380T with this inhibitor, a result 
similar to that obtained for its parent molecule, lisinopril (table 4.4, figure 4.5).  The V379S 
mutation caused an unexpected decrease in Ki from that of the C-domain for all of the C-
selective inhibitors containing a P2’ Trp: RXPA380 (table 4.2, figure 4.3), kAW (table 4.3, 
figure 4.4) and lis-W (table 4.4, figure 4.5).  Moreover, an N-domain mutant S357V (kindly 
provided by R. G. Douglas), which is a soluble N-domain construct containing the 
corresponding tACE V379 residue in position 357, displayed a Ki of 320 %M  for RXPA380 
(result not shown), demonstrating a decrease in affinity for this inhibitor compared to that of 
the N-domain. These data confirm the unexpected observation seen with the tACE V379S 
mutant, that a Ser in this position favours the binding of a Trp moiety.
The decrease in affinity demonstrated by V380T with RXPA380 is probably due to the 
decreased hydrophobicity resulting from the Val to Thr conversion (Figure 4.6).  Similar 
changes in affinity were observed for kAW and kAF.  The relatively minor shifts displayed by 
mutations within this pocket are probably due to the excess space available between the 
inhibitor and the S2’ residues.  For example, in the tACE-RXPA380 structure (Corradi et  al., 
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2007), E376 and D453 are 5.9 and 5.5 Å from the RXPA380 Trp, respectively  (figure 4.6A). 
It can therefore be suggested that the design of compounds with more extensive non-polar or 
negatively charged P2’ substituents could potentially  lead to considerably  increased domain-
specific inhibition due to favourable hydrophobic or electrostatic interactions with the tACE 
S2’ pocket.  Furthermore, it is important to note that the architecture of the S1’ and S2’ pockets 
together essentially form a continuous chamber within the active-site.  This therefore allows 
for even more latitude for positioning of P1’ and P2’ moieties.
For lisinopril and lis-W, V380T caused 4- and 6-fold increases in affinity, respectively (table 
4.4).  A closer look at the alignment of the crystal structures of these two inhibitors in 
complex with tACE, with the crystal structure of the N-domain  (Natesh et al., 2003; Corradi 
et al., 2006; Watermeyer, 2008) revealed that the N-domain Thr was 4.7 and 4.5 Å from the 
inhibitors’ P1’ lysyl amine groups, for lisinopril and lis-W respectively  (figure 4.9).  Being 
within 5 Å, these side-chains would therefore be able to form favourable water-mediated 
interactions, which could account for this increase in affinity.
Interestingly, the V379S mutation caused an increase in affinity  for all of the inhibitors 
containing a Trp  in the P2’ position - a result that was contrary to that expected with a P2’ 
decrease in hydrophobicity.  Although this result is not readily explained by the crystal 
structures (Corradi et al., 2006; Corradi et al., 2007; Natesh et al., 2003; Watermeyer et al., 
2008), it may be a consequence of a water-mediated hydrogen bond interaction between the 
Ser and indole N of the P2’ Trp, facilitated by  rotation about the RXPA380 '1 and '2 bonds of 
the P2’ substituent (figure 4.10).  Support  for this theory is provided by the fact that no change 
in affinity is observed for the V379S mutant with the C-domain-selective inhibitor kAF, 
containing a Phe in this position and therefore lacking a hydrogen-bond acceptor.  This idea is 
further emphasised by the decrease in affinity displayed by the N-domain S357V mutant for 
RXPA380 (Ki = 320 %M).  This N-domain construct lacks a potential hydrogen-bond donor 
group in this position as a result of the tACE Val substitution.
To further understand the results obtained with the single S2’ mutants (see table 2.1), two 
multiple S2’ mutant proteins were generated: one containing an N-domain S2’ pocket 
(TEVVD), where all the unique C-domain residues were substituted by their corresponding 
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N-domain counterparts, and a similar protein lacking the V379S mutation (TEVD).  For 
RXPA380, the TEVD mutant demonstrated a 32-fold decrease in affinity  from tACE, 
compared to the 16-fold decrease displayed by the full N-domain S2’ pocket construct, 
TEVVD (table 4.2, figures 4.4 and 4.6).  Hence, the introduction of a Ser in the V379 position 
to the TEVD construct (TEVVD) caused a smaller change in affinity from tACE than that of 
TEVD, which is not surprising given the result of the single V379S mutation.  Therefore, the 
presence of a Val in position 379 of tACE (or 357 in the N-domain) seems to decrease the 
affinity for RXPA380, while the presence of a Ser in this position causes the opposite effect.  
Figure 4.10.  Stick representation of RXPA380 within the active-site of tACE (green 
cartoon).  The zinc ion is represented as a purple sphere, and residues V379 and E376 are 
indicated.  In the V379S mutant, rearrangement of protein and inhibitor side-chains within the 
S2’ pocket (indicated by the red and blue arrows) could allow for the formation of water-
mediated interactions to occur between the indole N of the inhibitor Trp and the Ser residue. 
This effect could result in an increased affinity for RXPA380 by this mutant  compared to 
tACE.  This image was created in Discovery Studio version 1.6 (Accelrys, Cambridge, UK).
This effect was not displayed by lis-W.  A marked increase in Ki was observed for both the 
TEVD and TEVVD constructs, the more considerable shift  being demonstrated by the full S2’ 
mutant, TEVVD (16-fold from tACE versus 11-fold for that of TEVD) (table 4.4, figure 4.5). 
Therefore, it is interesting that the V379S mutation alone causes an increase in affinity  for lis-
V379S
E376
Chapter 4: Kinetic Characterisation of tACE Constructs
82
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
W, as observed with RXPA380, while combined with the N-domain-like S2’ pocket it 
facilitates a decrease in binding.  This could perhaps be explained by a combined effect of the 
complete N-domain-like S2’ pocket and the different positioning of the P2’ Trp of lis-W 
compared to that of RXPA380, evident from the two crystal structures, not allowing the 
rearrangement of residues to facilitate the formation of a water-mediated hydrogen bond 
interaction (discussed above).
4.3.5.5 Effect of a combined N-domain S2’ pocket and F391Y mutation on RXPA380 
binding
The tACE protein S2’F, containing N-domain S2’ pocket residues (as for mutant TEVVD) as 
well as the S2 F391Y mutation (see table 2.1), was used to investigate the combined 
contribution of these two sub-sites to domain selectivity.  S2’F demonstrated an approximately 
80-fold decrease in affinity for RXPA380 over tACE, the largest shift observed among all the 
mutants (table 4.2, figure 4.6A).  
The N-domain Ki for RXPA380 was however approximately  10 times higher than that of the 
S2’F construct.  This suggests that residues within the other pockets of the active-site might 
also contribute to the overall selectivity f this inhibitor, for example V518.  Furthermore, 
there may be additional indirect factors that play a role in the marked specificity of RXPA380, 
such as scaffolding residues affecting the conformation or positioning of conserved residues 
important for selective binding of inhibitors.  
Interestingly, this phenomenon has been demonstrated with cyclic nucleotide 
phosphodiesterases (PDEs) 4 and 7 (Wang et al., 2005).  PDEs contain conserved catalytic 
domains involved in the hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate (cGMP) (Antoni, 2000; Carvajal et al., 2000), and although PDE4 
and 7 both show a preference for the hydrolysis of cAMP, PDE4-selective inhibitors are not 
able to block PDE7 hydrolysis (Gardner et al., 2000; Hetman et al., 2000).  To elucidate this 
selectivity, Wang et al. mutated key residues within PDE7 and analysed their effect on 
binding of rolipram, a PDE4-specific inhibitor (Wang et al., 2005).  They found that only the 
combined effect of multiple residues caused a shift in rolipram-selectivity of PDE7 to that of 
wild-type PDE4.  Most interestingly however, this combination included substitution of a 
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scaffolding residue (Y329 in PDE4, S373 in PDE7) interacting with an amino acid conserved 
between these enzymes (N369/413 in PDE4/7).  The PDE4-rolipram crystal structure revealed 
that Y329 stabilises the Q369 side-chain via a hydrogen bond interaction (figure 4.11) (Huai 
et al., 2003).  Substitution of this Tyr with S373 in PDE7 results in the hydrogen bond 
interaction occurring with S377, displayed in the PDE7A1-IBMX structure (PDE7 in complex 
with a non-selective PDE inhibitor), thus changing the positioning of the Gln side-chain and 
probably  abolishing the hydrogen bond interaction with rolipram (figure 4.12) (Wang et al., 
2005).  To investigate the potential for this phenomenon contributing to ACE domain 
selectivity, a detailed analysis of scaffolding residues supporting invariant residues known to 
be important for inhibitor binding would be required.  This would need to be followed by 
mutational and kinetic studies of constructs containing a combination of active-site 
substitutions, as well as scaffolding residues identified to potentially play a role in inhibitor 
selectivity.
Figure 4.11.  Stick representation of rolipril (yellow) within the active-site of PDE4 (PDB 
code 1oyn) aligned with PDE7A1 (1zkl) (taken from (Wang et al., 2005)).  PDE4 residues 
binding rolipril are shown in cyan (blue labels) and corresponding PDE7 residues are 
represented in green (red labels).  Hydrogen bond interactions are indicated by dotted lines.
FIG. 4. The inhibitor binding. A, stereoview of electron density for IBMX. The (2 Fo! Fc) map was calculated from the structure with omission
of IBMX and contoured at 1!. B, IBMX (golden sticks-balls) binding to the active site of PDE7A1 catalytic domain. The hydrogen bonds are
represented by dotted lines. C, superposition of rolipram binding residues of PDE4D2 (cyan sticks and blue labels) over those of PDE7A1 (green
sticks and red labels). The cyclopentanyl ring of rolipram will clash with the side chain of Ile-412 if Gln-413 forms hydrogen bonds with the oxygen
atoms of phenylmethoxy of rolipram. D, surface presentation of the subpocket for the cyclopentanyl group of rolipram in PDE4D2. E, surface
presentation for the same binding pocket in PDE7A1. It is clear that the size and shape of the subpocket for the cyclopentanyl group are different.
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4.3.6 Roles of tACE active-site residues in binding of the N-domain-selective inhibitor 
RXP407
RXP407 displays a 538-fold selectivity for the N-domain (figure 4.12).  To explore the 
molecular basis for this specificity, selected single and multiple tACE mutants were tested to 
analyse the effect of mutations on the affinity of RXP407.  The single mutations had little 
effect on their affinity for this inhibitor compared to wild-type tACE, with the biggest 
increase (8.5-fold) displayed by V379S (table 4.2, figure 4.12).  The V379S conversion would 
increase the hydrophilicity  of the S2’ pocket.  This could lead to more favourable binding to 
the carboxyamide moiety on RXP407’s P2’ Ala, believed to play a critical role in RXP407’s 
N-selectivity.  
The multiple mutants however, displayed more marked shifts in Ki from that of tACE.  The 
TEVVD construct demonstrated a slight decrease in Ki of appr ximately 4-fold from that of 
the C-domain, still 146-fold higher than that of the N-domain (figure 4.12).  Interestingly 
however, this mutant protein combined with the F391Y mutation (which alone only  showed a 
2-fold shift from tACE), presented with a 175-fold increase in affinity compared to tACE, 
resulting in a Ki value only 3-fold higher than that of the N-domain (figure 4.12).  This 
marked change in Ki observed for the multiple S2’F mutant confirms the overall importance of 
the active-site residues in RXP407 selectivity, and emphasises the co-operative effects of 
combined active-site residues.  Furthermore, factors affecting selectivity  may not be limited to 
the active-site residues interacting directly with the inhibitor (discussed in section 4.3.5.5).
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Figure 4.12.  Log scale comparison of the relative binding affinities of tACE active-site 
mutants for the N-selective RXP407 with that of wild-type N-domain.  Values below the 
dashed line represent an increase in affinity  relative to that  of tACE, towards a more N-
domain-like Ki.  
4.4. Summary
The two single mutations that caused the biggest increase in tACE Ki for RXPA380 and the 
keto-ACE inhibitors were F391Y and V518T, respectively.  Most  of the point mutations 
within the S2’ pocket caused a slight decrease in affinity for these inhibitors, however V379S 
caused an unexpected increase in affinity relative to wild-type tACE.  The combined effect of 
multiple substitutions within the S2’ and S2 pockets demonstrated the most notable shift in Ki 
for all of the inhibitors tested (RXPA380, RXP407 and lis-W).  Furthermore, the combined 
effect of the S2’ pocket alone (TEVVD) displayed an additive effect on the change in affinity, 
while interestingly, inclusion of the F391Y mutation in this construct resulted in a more co-
operative effect on the binding of both the phosphinic inhibitors, where the change in Ki is 
greater than the sum of the individual changes for the single mutants concerned.
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This confirms the overall importance of these residues in the C- and N-specificity  of ACE 
inhibitors, and highlights the fact that domain selectivity is the result of a combination of 
residues and possibly other factors too, and therefore cannot be attributed to a single amino 
acid.  However, we have shown that residues within the S2 (F391), S1 (V518) and S2’ (V379, 
E367) play a major role in the C-selectivity of ACE.
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Conclusions
This study describes an investigation into understanding the molecular determinants of ACE 
domain selectivity  involving a combination of mutational and kinetic approaches.  A series of 
tACE mutants was generated containing specific single and multiple C-domain active-site 
replacements.  These constructs were subsequently used to characterise domain-specific 
interactions using two fluorogenic peptides, Abz-LFK(Dnp)-OH (C-specific) and Abz-
SDK(Dnp)P-OH (N-specific), and a panel of domain-selective inhibitors. 
The domain specificity of both Abz-LFK(Dnp)-OH and Abz-SDK(Dnp)P-OH has been 
attributed to the high catalytic efficiency with which the C-domain and N-domain of ACE 
cleave these peptides, respectively (Araujo et al., 2000; Bersanetti et al., 2004).  This was 
demonstrated here with the C-selective substrate, but the kcat for the N-domain with Abz-
SDK(Dnp)P-OH was only 4-fold higher than that of its C-domain counterpart.  The low 
catalytic rate observed in this study is possibly due to the use of the soluble single N-domain, 
as opposed to the full-length protein with an inactivated C-domain (Araujo et al., 2000).  This 
result suggests that the marked N-specificity observed by Araujo et al. for Abz-SDK(Dnp)P-
OH could be due to interactions between the two ACE domains of the full-length protein, 
which would be absent in single soluble domains.
Modest decreases (3-fold) in the catalytic efficiency of Abz-LFK(Dnp)-OH cleavage were 
displayed by  the two substitutions D377Q and V380T.  As these substitutions do not directly 
affect any of the residues stabilising the transition state (being more than 10 Å away), it  is 
likely that they  might introduce unfavourable interactions with the substrate P1’ Phe, which 
could change the orientation of Abz-LFK(Dnp)-OH within the active-site, resulting in 
unfavourable interaction with these stabilising residues, thereby reducing the efficiency with 
which the substrate is cleaved.
None of the mutants tested resulted in acquisition of N-domain-like catalytic efficiencies for 
either Abz-LFK(Dnp)-OH or Abz-SDK(Dnp)P-OH.  This suggests that other residues within 
the active-site, and perhaps indirect factors such as substrate access and interaction with 
residues elsewhere in the enzyme, such as the lid region, might contribute to domain 
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specificity.  Unfortunately, due to limited substrate availability, the multiple mutants were not 
tested with the domain-selective fluorogenic substrates.  This phenomenon has, however, been 
observed with a C-domain construct containing an N-domain-like lid, which displayed a 
marked shift in kcat for Abz-LFK(Dnp)-OH toward that of the N-domain.
The panel of inhibitors used to characterise the tACE active-site mutants consisted of the 
highly  potent, C- and N-selective phosphinic peptide inhibitors RXPA380 and RXP407 (Dive 
et al., 1999; Georgiadis et al., 2003); the modestly C-selective keto-ACE and its C-selective 
derivatives kAW and kAF (Weare et al., 1981; Redelinghuys et al., 2006); and the slightly C-
selective lisinopril along with its analogue lis-W, containing a P2’ Trp moiety  for improved C-
specificity (Nchinda et al., 2006a).
Interestingly, the S2 F391 residue proved to be critical for the high C-specificity of RXPA380, 
with the F391Y mutant displaying a 34-fold decrease in affinity  for this inhibitor compared to 
wild-type tACE.  This effect is probably due to the loss of an important aromatic interaction 
between F391 and the P2 Phe, as well as some potential steric hindrance resulting from the 
introduction of a Tyr at this position.
In the S1 pocket, V518 seems to play  a crucial role in the 30-fold specificity of keto-ACE, as 
evidenced by the acquisition of an N-domain-like Ki for this mutant.  Both kAW and kAF also 
demonstrated marked decreases in affinity for this mutant.  This substitution causes a 
reduction in the hydrophobicity of the S1 pocket, which could lead to less favourable 
interactions and therefore decreased binding of these inhibitors.
E162 is an S1’ residue believed to play  an important role in the C-selectivity of lisinopril and 
lis-W due to its favourable electrostatic interaction with the P1’ Lys, which seems to be 
lacking in the N-domain structure.  Surprisingly, substitution of E162 with the N-domain Asp, 
did not cause a change in affinity for either of these inhibitors.  This could be due to the 
scaffolding and/or backbone residues of the C-domain, which may orient the Asp in E162D to 
maintain favourable interactions with the P1’ side-chain, while the N-domain residues may not 
cause the same effect.
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For most of the single S2’ mutants, only slight decreases in affinity were observed for the 
inhibitors tested, the most notable of these displayed by  V380T and E376D for RXPA380, 
kAW and kAF.  Lis-W also showed a decrease in affinity for the latter mutant, however an 
increase was observed for V380T.  These modest decreases are probably due to the space 
available within this large pocket, and the increase in affinity displayed by  V380T for lis-W is 
probably  due to an interaction with the P1’ moiety rather than interactions within the S2’ 
pocket.  
Intriguingly, V379S, which abrogates hydrophobic interactions with the P2’ group, caused an 
unexpected decrease in Ki for all of the inhibitors containing a P2’ Trp substituent.  This result 
was supported by  a corresponding N-domain mutant (S357V), which displayed an increase in 
affinity for RXPA380 compared to that of the wild-type N-domain.  Furthermore, the full 
tACE S2’ mutant (TEVVD) displayed less of a decrease in affinity  for RXPA380 compared to 
the similar mutant lacking this V379S substitution (TEVD).  Therefore the presence of Val in 
this position (379 in tACE, 357 in N-domain) seems to decrease the affinity of RXPA380, 
while exchange of this residue for Ser has the opposite effect.  This result could be explained 
by rotation about the '1 and '2 bonds of the inhibitor P2’ Trp, enabling the formation of a 
water-mediated hydrogen bond interaction between the inhibitor-Trp indole N and the 
hydroxyl of the Ser residue.
Of the single mutant constructs tested with the N-specific RXP407, V379S displayed the 
highest increase in affinity (8.5-fold).  This effect is probably due to the increase in 
hydrophilicity brought about by the presence of the Ser substituent, resulting in more 
favourable interactions with the amidated C-terminus of the inhibitor.
The multiple S2’ mutant constructs, TEVD and TEVVD, displayed an additive effect on the 
change in affinity  for the inhibitors tested: RXPA380, RXP407 and lis-W.  Interestingly, when 
the TEVVD construct was combined with the S2 F391Y substitution (S2’F), the resulting 
construct demonstrated a marked decrease and increase in affinity  for RXPA380 and RXP407, 
respectively, indicating a strong co-operative effect on domain specificity.  The inhibition 
constants for the N-domain were, however, 10- and 3-fold higher and lower for RXPA380 and 
RXP407, respectively, suggesting that there may  be additional effects from other active-site 
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residues (such as V518).  Moreover, indirect factors such as scaffolding residues supporting 
invariant residues critical to inhibitor binding could play a role in conferring domain 
specificity.  
We have identified a number of elements within the active-site of tACE that clearly  play  a 
critical role in the C-domain-specificity of this enzyme, namely F391 (S2), V518 (S1), E376 
(S2’) and V380 (S2’).  We have also shown that multiple residues in the S2’ pocket have an 
additive effect on affinity for domain-specific inhibitors, while these residues combined with 
residues in other pockets, such as F391, display a strong co-operative effect on domain-
specificity.  
Based on this work, a number of suggestions can be made for the development of improved 
domain-specific ACE inhibitors.  Firstly, the space available in the S2’ pocket could be more 
extensively  exploited using moieties that are larger and more rigid than Trp.  This could allow 
stronger and more favourable interactions with unique C-domain S2’ residues, resulting in a 
higher affinity for this domain.  Furthermore, it is important to note that the continuous 
chamber formed by  the S1’ and S2’ sub-site pockets allows even more latitude for the 
architecture of P1’ and P2’ side-chains.  Finally, hydrophobic contacts between the inhibitor P2 
and P1 substituents and C-domain F391 and V518, respectively, seem to markedly contribute 
towards the C-domain specificity  of the inhibitors tested in this study, particularly in 
combination with interactions in the C-domain S2’ pocket.
Further elucidation of the molecular basis for the complex domain selectivity of ACE could 
involve the generation of more multiple mutants incorporating active-site residue 
substitutions, such as V518T (S1 pocket) into the S2’F, in tACE as well as sACE, and 
analysing the combined effect of these constructs on specificity.  Moreover, these multiple 
mutants could be combined with substitutions of variant scaffolding residues stabilising 
conserved side-chains important for the binding of C-domain-specific inhibitors.  Another 
approach one could employ would be isothermal titration calorimetry, to directly  assess the 
changes in binding affinities and thermodynamic parameters of inhibitors with these mutant 
proteins.
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This work provides critical and important insight into the molecular determinants of ACE 
domain specificity.  It therefore paves the way for rational design of more efficient domain-
specific inhibitors, which could ultimately lead to the development of more efficient therapies 
for the treatment of cardiovascular disease.
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Appendix I
All methods in this appendix were adapted from those in Ausubel et al. (1992), unless 
otherwise stated.
Cloning and Mutagenesis
Restriction enzyme digests
Digest reaction mixtures (2 µL 10 x restriction buffer, 1-3 µL 1 µg.µL-1 plasmid DNA and 5 
units of each restriction enzyme, volumes made up to 20 µL with sterile dH2O) were 
incubated at 37oC for 1 hour.  Mini-preparation DNA (20 µL) screening digests were stopped 
with 2.5 µL restriction enzyme STOP buffer (8 parts 6 x loading buffer (0.25 % bromophenol 
blue, 0.25 % xylene cyanol, 30 % glycerol) and 1 part 0.5 M EDTA, pH 8.0).
Agarose gel electrophoresis
Samples containing 2 µL 6 x loading buffer and 20 µL digest reaction mixtures, or uncut 
DNA (1-2 µL of 1 µg.µL-1), as well as 8 µL lambda DNA digested with EcoRI + HindIII (40 
µL 553 µg.mL-1 lambda DNA, 16 µL 10 x restriction buffer, 50 units EcoRI, 50 units HindIII, 
volumes made up to 160 µL with sterile dH2O), were loaded onto a 6 x 10 cm agarose gel (0.8 
% agarose in 1 x Tris-borate/EDTA (TBE) buffer (0.045 M  Tris-borate, 0.001 M EDTA) with 
0.3 µg.mL-1 ethidium bromide).  Electrophoresis was performed at 70 V for approximately  1 
hour in 1 x TBE buffer with 0.3 µg.mL-1 ethidium bromide.  DNA bands were visualised 
using a UV light source, and photographed directly. 
Preparation of E. coli JM109 competent cells using RbCl
This method was adapted from that reported in Hanahan (1983).  Five mL of Luria-Bertani 
(LB) broth (10 g.L-1 tryptone, 5 g.L-1, 172 mM NaCl) was inoculated with a colony of JM109 
cells and shaken at 37oC overnight.  This starter culture was inoculated into 50 mL LB broth 
and shaken at 37oC until the cell growth had reached logarithmic phase (OD530=0.35).  The 
culture was then chilled on ice for 15 minutes, and centrifuged at 4000 x g for 5 min at 4oC. 
The pellet was resuspended in 21 mL ice-cold TF buffer 1 (100 mM RbCl, 50 mM MnCl2, 30 
mM KOAc, 10 mM CaCl2, 15% glycerol) and incubated on ice for 90 min.  Cells were 
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harvested by centrifugation at 4000 x g for 5 min at  4oC, and the pellet was resuspended in 
3 mL TF buffer 2 (10 mM Morpholinepropanesulphonic acid pH 7.0, 10 mM RbCl, 75 mM 
CaCl2, 15% glycerol).  200 µL aliquots were frozen in liquid N and stored at –80oC.
Coding sequence of 3’ end of pcDNA-tACE!36NJ with new stop codon
1801      CTCCGCACGGAGAACGAGCTGCATGGGGAGAAGCTGGGCTGGCCGCAGTATAACTGGACG
601        L  R  T  E  N  E  L  H  G  E  K  L  G  W  P  Q  Y  N  W  T  
1861      CCGAATTCCTAG
621        P  N  S  *  
Original primers used for T282S and V380T mutations
Figure A1.  Original primers used for T282S  and V380T mutations.  Primers produced no 
positive clones.  Complementary mutagenic primers (For, forward; Rev, reverse) were 
designed containing the mutation of interest, as well as a silent mutation introducing a unique 
restriction endonuclease site (RE) to facilitate screening.  Residues in bold indicate the codon 
to be mutated, unique restrictions sites are underlined.
Mutant Primer                  RE
T282S  For 5’-CTACTGGGGAACATGTGGGCGCAGAGTTGGTCCAACATCTATGAC-3’ 
 Rev 5’-GTCATAGATGTTGGACCAACTCTGCGCCCACATGTTCCCCAGTAG-3’       BmrI
V380T  For 5’-GTTAACTTGGAGGACCTGGTGACGGCCCAC-3’  
 Rev 5’-GTGGGCCGTCACCAGGTCCTCCAAGTTAAC-3’                          HpaI
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Appendix II
Substrate kinetics
Preparation of synthetic substrates
5.7 mM HHL working solution
19.4 mg HHL was added to 1.67 mL 0.28 M NaOH and heated to dissolve the solid.  832 µL 
0.5 M HEPES (pH 7.5), 2.498 mL 1 M NaCl and 2.998 mL dH2O was added to this solution.
1 mM Z-FHL working solution
A 20 mM  stock solution of Z-FHL was made up by  dissolving 220 mg Z-FHL in 2 mL 0.28 M 
NaOH, and making up to 20 mL with dH2O.  This solution was stored in 1 mL aliquots at 
-20oC.  
Working solutions of Z-FHL were made up by first adding 15 mL dH2O to 4 mL 5 x 
phosphate buffer (0.5 M KPO4 buffer, pH 8.3, 1.5 M NaCl), then adding 20 µL 10 mM ZnSO4 
to this buffer, followed by 1 mL 20 mM Z-FHL.
Standard curve for fluorogenic peptide 
The change in fluorescence from baseline levels (before addition of ACE) to total hydrolysis 
of a range of substrate concentrations (0- 2.5 nmoles) was measured at  $ex = 320 nm and $em = 
420 nm.  A standard curve was generated by  plotting this change in fluorescence versus 
nmoles of substrate hydrolysed.  The slope of the linear regression curve fitted to this plot was 
determined using GraphPad Prism 4.01.
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